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Abstract 
 
DAX-1 is a member of the Nuclear Hormone Receptor superfamily and acts as a transcriptional 
repressor. DAX-1 plays an important role in the development of adrenal and gonadal tissues. In 
addition to its role in normal cell development and differentiation, DAX-1 appears to have some 
influence on the progression of cancer. This work aims to examine the role of DAX-1 in 
regulation of proliferation in breast cancer. In our study, we have expressed DAX-1 in a DAX-1 
deficient breast cancer cell line as well as knocked down DAX-1 expression in normal DAX-1 
positive breast cells. Through these experiments, we were able to identify DAX-1 target genes 
and effect a change in proliferation rate.  
In an effort to better understand DAX-1 function both in normal and disease states we also 
examined one type of posttranslational modification, SUMOylation. SUMOylation involves the 
addition of the small polypeptide conjugate SUMO (Small Ubiquitin-like Modifier) to proteins. 
SUMOylation can have a variety of effects on target proteins including changes in localization, 
protein-protein interaction, interaction with DNA, and in some cases stabilization of the target 
protein. SUMOylation of nuclear hormone receptors can have profound effects on their function. 
To study the effects of SUMOylation on DAX-1, the overall SUMOylation status of DAX-1 in 
mammalian cell lines was determined. It was found that DAX-1 is SUMOylated in several cell 
lines, both normal and carcinoma cells. Mutations were made in putative SUMOylation sites 
within the DAX-1 gene. Mutants were then transfected and assayed for changes in gene 
expression and activity. It was determined that mutating either of two putative SUMOylation 
sites led to a loss of DAX-1 repressive function when compared to wild-type DAX-1.  
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Chapter 1: General Introduction 
 
NHR overview  
Nuclear hormone receptors (NHR) are ligand activated transcription factors that act as 
on-off switches to drive the expression or repression of target genes [1]. These proteins make up 
the largest family of eukaryotic transcription factors and regulate a diverse range of functions in 
the body including regulation of metabolic homeostasis, development and differentiation, 
reproductive development and maintenance of adult reproductive tissues, as well as salt balance 
[2]. Nuclear hormone receptors bind to specific sequences of DNA found upstream of target 
genes called hormone response elements (HRE). NHRs form dimers on the HREs and these 
dimers can be either homomeric, meaning they are comprised of two identical receptor 
monomers, or heteromeric and made up of two different types of receptor monomers.  NHRs 
typically contain two conserved domains: a DNA binding domain (DBD) and a ligand binding 
domain (LBD). Ligands bound by NHRs include both steroid hormones, such as estrogen and 
testosterone, as well as nonsteroid hormones such as retinoic acid, thyroid hormone, and vitamin 
D [1]. To become activated, a ligand binds to the LBD of a nuclear hormone receptor resulting in 
a conformational change that allows the NHR/ligand complex to bind DNA at a HRE and 
regulate expression of a specific target gene. Typically, binding of a NHR can trigger the 
recruitment of other transcription factors, resulting in activation and expression of the target 
gene. However, NHRs can also act as negative regulators and alter the activity of other 
transcription factors leading to a reduction in expression of target genes.  
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Figure 1-1 Typical nuclear hormone receptor structure.  
Diagram showing the typical structure of an NHR. 1D shows amino acid sequence of conserved 
domains of a nuclear receptor: N-terminal domain (A/B), DNA binding domain (C), flexible 
hinge region (D), ligand binding domain (E), and the C-terminal domain (F). 3D shows 
crystallographic structures of DNA binding domain and ligand binding domain.  
(Boghog2. Nuclear Receptor Structure.12/03/2014. 
http://commons.wikimedia.org/wiki/File:Nuclear_Receptor_Structure.png) 
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Currently, there are 48 known nuclear hormone receptors in humans including receptors 
for which the ligands are known, adopted orphans for which the ligands were previously 
unknown, and orphan receptors for which there is no known ligand [3].  
 
 
NHR Structure 
The typical NHR consists of a variable N-terminal region, a conserved DNA binding 
domain (DBD), a hinge or linker region, a conserved ligand-binding domain (LBD), and a highly 
variable C-terminal domain, as shown in Figure 1-1 [4]. The N-terminal region varies among 
NHRs and contains a region that has ligand-independent transcriptional activity termed the 
activation function 1 (AF-1) [5]. The DBD gives NHRs their specificity in binding to hormone 
response elements (HRE) within the DNA. The DBD of an NHR typically binds two hexameric 
nucleotide sequences, called half-sites, that compose the HRE [6]. NHRs can bind as monomers 
to a single half-site, or as homodimers or heterodimers to a set of two half-sites. Specificity of 
binding between NHRs and the DNA of a HRE is conferred by the nucleotide sequence present 
in a given half-site, the relative orientation of half-site pairs, and the amount of space between 
half-sites [6, 7]. These three factors determine whether a monomer, homodimer, or heterodimer 
pair of nuclear hormone receptors will bind. The DBD is composed of two zinc finger motifs, 
each made up of approximately 70 amino acids forming two α-helices oriented perpendicularly 
from one another as seen in Figure 1-2. Zinc fingers mediate protein binding to HREs and help to 
stabilize the NHR complex [8]. Connecting the DBD to the LBD is a hinge region that allows 
flexibility of the protein so that it can interact with both ligands bound to the LBD and to 
response elements in the DNA at the same time.  
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Figure 1-2 DNA binding domain bound to HRE in DNA. 
The zinc fingers of a heteromeric pair of a nuclear hormone receptors binding to the DNA half 
site within a hormone response element (HRE) in double stranded DNA.  
(Boghog2. PPARg RXRa.12/03/2014. 
http://commons.wikimedia.org/wiki/File:PPARg_RXRa_3E00.png) 
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Structurally the ligand-binding domain is composed of three layers of α-helices that run 
antiparallel to one another forming what is known as the α-helical sandwich fold. The α-helical 
sandwich is made up of three antiparallel α-helices forming the “filling” surrounded by two 
additional α-helices on one side and three on the other forming the “bread”. The innermost layer 
of α-helices forms a cavity that acts as the ligand-binding pocket as shown in Figure 1-3 [3]. 
Although the LBD is considered the most highly conserved domain in the nuclear hormone 
receptor family, the ligand-binding pocket is one of the least conserved regions among NHRs as 
this region is responsible for the specificity of ligand binding [3]. Ligands vary greatly among 
the NHRs, so there is considerable variation in the sequence specificity as well as size and shape 
of the ligand-binding pocket. A second activation domain (AF-2) is found within the LBD. 
Unlike the AF-1 domain, AF-2 domain is highly ligand dependent and is much less variable. 
 
 
DAX-1: A Unique NHR 
DAX-1 (Dosage sensitive sex-reversal adrenal hypoplasia X chromosome gene 1) 
encoded by the gene NR0B1 is a unique member of the nuclear hormone receptor family. The 
NR0B1 gene has a relatively simple structure of two exons separated by a single intron that 
encodes a 470 amino acid protein as seen in Figure 1-4 [9]. Exon 1 contains 1168 base pairs, 
exon 2 contains 245 base pairs and the intron is 3385 base pairs [10]. The DAX-1 structure 
differs from that of the typical NHR, in that DAX-1 is an orphan receptor, and, as such, has no 
known ligand [1].   
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Figure 1-3 General ligand-binding domain crystallographic structure.  
The ligand-binding domain consists of three layers of α-helices running antiparallel to one 
another, shown as colored ribbons. The innermost region of helices forms the ligand-binding 
pocket, shown filled with gray space filling ligand.  
(Boghog2. ROR3C. 12/03/2014.http://commons.wikimedia.org/wiki/File:RORC_3L0L.png) 
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Figure 1-4 NR0B1 and DAX-1 structure. 
NR0B1 gene is located on the p arm of the X chromosome between positions 21.3 and 21.2. The 
gene consists of two exons that encode for a 470 amino acid protein: DAX-1. The DAX-1 
protein consists of two regions, the DNA binding domain and the ligand binding domain.  
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In addition, DAX-1 lacks several of the typically conserved domains of NHRs. Rather 
than the conserved DBD containing two zinc fingers, the transactivational AF-1 site, and the 
typical hinge domain, DAX-1 contains alanine-glycine rich repeat sequences of 65-67 amino 
acids as well as three leucine motifs known as LXXLL boxes in the N terminal DBD region, as 
seen in Figure 1-5 [11, 12]. Additionally, the N-terminal domain of DAX-1 contains cysteine 
residues that are arranged in such a way that interaction with the zinc ion in zinc fingers of other 
nuclear hormone receptors is possible [13]. Though DAX-1 contains the conserved LBD, no 
ligand has been found to date. Examination into the structure of the ligand-binding pocket of 
DAX-1 has revealed that the typical hydrophobic core found in NHRs is absent. The result is the 
formation of a cavity that is much smaller than that of other NHRs, suggesting that no ligand is 
likely to be found for DAX-1 [1]. Therefore, DAX-1’s function seems to be purely ligand 
independent. 
 
DAX-1 Function  
The DAX-1 protein acts as a coregulator and transcriptional repressor of other NHRs. 
Typically coactivators bind the AF-2 domain of an activated NHR. However, DAX-1 is able to 
bind this same domain and repress transcriptional activity [14]. Upon binding of the AF-2 
domain, DAX-1 recruits corepressors such as N-CoR and Alien to the promoter region of target 
genes [15]. This type of repression mechanism is observed with multiple NHRs, such as estrogen 
receptor (ER) and liver receptor homolog 1 (LRH-1) as seen in Figure 1-6 [16]. Interaction with 
NHRs is thought to be mediated through the third LXXLL box as this box in particular has 
sequence homology to the AF-2 domain of other nuclear hormone receptors [17]. Mutation of 
this box results in an inability of DAX-1 to recruit  
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Figure 1-5 Comparison of typical NHR structure with DAX-1 structure. 
A: Typical NHR structure with regions A-E (previously described Figure 1-1) 
B: DAX-1 structure with repetitive domain (R) containing LXXLL repeat motif boxes and ligand 
binding-like domain (E). 
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and bind corepressors as well as the loss of repressive ability of DAX-1 on protein targets like 
steroidogenic factor 1 (SF-1) and ER [17]. This type of repressive interaction has been shown 
between DAX-1 and SF-1 [12, 18, 19]. SF-1, along with Wilms’ tumor 1 (WT1), is involved in 
the development of the gonads and regulates a number of target genes responsible for 
development of the testes [20]. DAX-1 and the corepressor Nuclear Receptor-corepressor (N-
CoR) act together to repress SF-1/WT1 transcriptional activity [18]. Additionally, it has been 
proposed that DAX-1 inhibits another testes specific factor, Nur77 [21]. For these reasons DAX-
1 is considered to be an anti-testes factor. Additionally, DAX-1 has been shown to inhibit the 
transcriptional activity of a broad range of other nuclear hormone receptors including estrogen 
receptor (ER)[17], progesterone receptor (PR)[22], liver receptor homologue-1 (LRH-1)[17], and 
androgen receptor (AR)[22].  
Another mode of repressional activity by DAX-1 can occur when NHR are inactive and 
have no ligand bound. DAX-1 contains a C-terminal transcriptional silencing domain that allows 
it to interact with corepressors such as N-CoR, silencing mediator of retinoid-thyroid receptor 
(SMRT), and Alien [21, 23].  This complex binds NHRs in the absence of ligand. In this state 
NHRs remain inactive and are unable to bind a ligand until a conformation change takes place.  
 
The Role of DAX-1 in Physiological and Developmental Processes 
DAX-1 plays a key role in the development and function of the adrenal gland and the 
hypothalamic-pituitary-gonadal axis. Mutations in the NR0B1 gene can have serious impacts on 
the development of the adrenal glands and the gonadal tissues.  
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Figure 1-6 Mechanism of DAX-1 mediated repression. 
The LXXLL box of DAX-1 binds the AF-2 domain of nuclear hormone receptors ER, SF-1, or 
others. DAX-1 recruits corepressors such as NCo-R and Alien. Corepressors bind to the 
promoter region of target genes and help to prevent transcription.  
(Image: Hai P. Nguyen) 
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Adrenal hypoplasia congenita (AHC) is rare congenital disorder that is characterized by an 
underdeveloped adrenal cortex and severe adrenal insufficiency [24]. There are two histological 
forms of adrenal hypoplasia congenita, which has an estimated frequency of 1:12,500 live births 
[25]. The miniature adult form presents with smaller than normal adrenal glands and is 
associated with central nervous system deficiencies as well as abnormal pituitary development 
and function. This form, however, is not associated with DAX-1. The cytomegalic form of AHC 
is associated with mutations in the NR0B1 gene. The adrenal gland develops with little or no 
cortex permanent zone and disorganized residual cortical tissue that contains vacuolated cells 
similar to those seen in the fetal adrenal cortex [25]. The result of these morphological 
differences is a nonfunctional adrenal cortex. The adrenal cortex is responsible for production of 
adrenal cortical steroid hormones, such as glucocorticoid, mineralocorticoid, and sex hormones. 
Without these hormones serious symptoms arise.  
This form of AHC predominantly affects males due to the fact that it is an X-linked gene. 
Patients generally begin to exhibit symptoms in early childhood. These symptoms include 
extremely low salt levels, hypoglycemia, dehydration, decreased appetite, hypotension, 
decreased levels of glucocorticoids and aldosterone, and increased levels of adrenocorticotropic 
hormone (ACTH) [26]. Without required treatment of mineralocorticoid and glucocorticoid 
replacement therapy, AHC would be fatal. Hypogonadotropic hypogonadism (HH) is a condition 
that is associated with AHC that some patients also develop. HH involves a decrease in 
gonadatropic hormones thereby preventing normal sexual development during puberty [27]. 
Testosterone replacement is given to AHC patients also exhibiting hypogonadotropic 
hypogonadism. In addition to AHC and HH, DAX-1 has also been shown to play a role in 
normal sex determination and development of the gonads. Male to female sex reversal in 
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individuals with a normal sex determining region Y (SRY) gene has been mapped to a region of 
the X chromosome that includes NR0B1. For this reason the NR0B1 gene is considered a likely 
candidate for causing dosage sensitive sex reversal (DSS) [25].   
Normally DAX-1 functions in the hypothalamic-pituitary-adrenal-gonadal (HPAG) axis 
and is expressed in both developing as well as adult tissues. During development, DAX-1 is 
expressed in the adrenal cortex, anterior pituitary, hypothalamus, and the gonad. Whereas in 
adult tissues, DAX-1 expression has been seen in the adrenal cortex, Stertoli and Leydig cells of 
the testis, theca, granulosa, and interstitial cells of the ovary, as well as very specific locations in 
the anterior pituitary and hypothalamus [25, 28].  
The expression of DAX-1 during both development and adulthood resembles that of 
another orphan nuclear hormone receptor, steroidogenic factor 1 (SF-1). SF-1 is well known for 
its regulatory role of the HPAG axis and is a transcriptional activator of genes in the steroid 
hormone biosynthesis pathway of the HPAG axis [28]. Similarly to what is seen with DAX-1, 
mutations in SF-1 can lead to adrenal failure and XY sex reversal. DAX-1 has been shown to 
repress SF-1 activity, thereby acting as an antagonist [28].  
DAX-1 is a global negative repressor of genes in the steroid hormone production 
pathway. Steroidogenesis is an essential process for fundamental physiological functions such as 
metabolism, salt and water balance, and reproduction. Steroid hormone production occurs in a 
variety of tissues most notably the adrenal glands, ovaries, testes, and the brain [29]. All steroid 
hormones are synthesized from cholesterol and are derived through a series of enzymatic 
reactions [29]. The first step in this process takes place in the mitochondria and involves the 
delivery of cholesterol from the outer mitochondrial membrane to the inner mitochondrial 
membrane [30]. This is the rate-limiting step in the enzymatic process and requires mediation by 
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the steroidogenic acute regulatory (StAR) protein [31]. StAR production is triggered by 
steroidogenic stimuli such as adrenocorticotropic hormone (ACTH) and angiotensin II (AII) 
[32].  DAX-1 is one of the key modulators of StAR transcription and therefore plays an 
important role in the regulation of steroid hormone production. DAX-1 exerts this inhibition by 
binding the StAR promoter region leading to a drastic decrease in StAR transcription [33]. 
 
 
The Role of DAX-1 in Breast Cancer 
The action of steroid hormones, most notably estrogens and progesterone, are extremely 
influential forces for the development and progression of breast cancer. Additionally, androgens 
can play a role in breast cancer because of their ability to be converted into estrogens [34]. 
Estrogen signaling in the breast plays a driving role in proliferation. There are two forms of ER, 
estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) [35]. Each is encoded by a 
different gene, but share similar homology. Additionally, the two forms of ER have somewhat 
different functions, with ERα being the primary form responsible for proliferation and growth 
[36]. Typically, estrogen receptor (ER) binds its ligand, estrogen (17β-estradiol), becomes active, 
translocates from the cytosol to the nucleus, and moves to estrogen response elements (ERE) in 
DNA. Estrogen receptor can form a homodimer with two receptors of one form, either ERα (αα) 
or ERβ (ββ) or form a heterodimer with one type of each receptor ERαβ [36]. The activated 
receptor can then drive transcription of target genes.  
One important target gene of ER is Cyclin D1 (CCND1). Cyclin D1 is a critical cell cycle 
control protein whose transcriptional regulation is responsible for mediating the transition from 
G1 to S phase of the cell cycle [34]. Not only has over-expression of Cyclin D1 been shown to 
increase breast cancer growth, it also plays a driving role in breast cancer progression [37, 38]. 
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Additionally, Cyclin D1 expression has also been linked to the development of resistance to 
tamoxifen antiestrogen therapy [39].  Cyclin D1 is a key proliferation target of estrogen receptor 
and drives progression through the cell cycle. ER positive breast cells proliferate in the presence 
of estrogen. Estrogen-dependent proliferation occurs in both normal, healthy cells and in cancer 
cells.   
 DAX-1 is a known repressor of estrogen receptor and has been show to reduce ER 
transcriptional activity [17]. Recent research has elucidated a relationship between estrogen 
receptor, androgen receptor, and DAX-1, showing that AR may repress ER activity by activating 
DAX-1 in estrogen-dependent breast cancer cells [40].  ERα positive cells treated with non-
aromatizable androgen 5-α-dihydrotestosterone (DHT) had decreased Cyclin D1 expression and 
this reduction in Cyclin D was mediated through AR recruitment of DAX-1 [38, 40]. Increased 
transcription of DAX-1 by AR leads to inhibition of ER transcription of Cyclin D1, therefore 
slowing the rate of proliferation in breast cancer cells. Androgens have been shown to have a 
variety of effects on both normal and diseased states of the breast. Androgen signaling has 
primarily inhibitory effects on the growth of normal breast cells and appears to act as a protective 
force in breast cancer [41, 42]. Activation of AR by it’s natural ligand dihydrotestosterone 
(DHT) or a synthetic analog significantly increased DAX-1 levels, resulting in an inhibition of 
the proliferation of MCF7 breast cancer cells [40]. However, in some studies androgens have 
been shown to enhance breast cancer development and growth [43].  
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Chapter 2: Introduction 
 
 Previous research has shown that DAX-1 is a negative repressor of estrogen receptor 
transcriptional activity [40, 44].  However, the precise mechanism of repression and the 
complement of downstream target genes affected by DAX-1 activity are unknown. In estrogen 
receptor positive breast cancer, the binding of estrogen to ER drives proliferation through the cell 
cycle causing cells to divide and multiply. One of the mechanisms by which ER drives 
proliferation is by transcription of the Cyclin D1 gene. Cyclin D1 is a cell cycle control protein, 
which mediates the transition from G0/G1 into S phase of the cell cycle. During G0/G1 a cell is 
metabolically active, but is in arrest and it is not actively progressing through the cell cycle. 
However, in G1 a cell will begin the preparations for S phase. During DNA synthesis, or S 
phase, the DNA content of the cell is copied so that the cell can later divide into two new 
daughter cells. Accumulation of Cyclin D propels the cell through G1 and into S phase. Without 
enough Cyclin D present, the cell will not enter S phase of the cell cycle, but will stay arrested in 
G1. Previous research (Tzagarakis-Foster, unpublished) has shown that in a subset of breast 
cancer patients, DAX-1 is expressed in normal tissue of the breast, but expression is down 
regulated or absent in patient matched tumor tissue (Figure 2-1). This observation has led to the 
hypothesis that DAX-1 acts a protective force in breast cells and the loss of its expression can 
lead to a more proliferative phenotype.  
To better understand the role of DAX-1 mediated repression and the downstream genes 
affected by its presence, I have examined both a DAX-1 deficient ER positive breast cancer cell 
line (MCF7) and a DAX-1 positive, ER negative normal epithelial breast cell line (MCF10A).   
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Figure 2-1 DAX-1 mRNA expression from 12 patient cDNA samples. 
DAX-1 expression data from 12 patient samples. Normal breast tissues are shown with white 
bar, cancerous breast tissues are shown with dark bar. 10/12 patients had higher DAX-1 
expression in normal tissue compared to cancer tissue. Expression level is measured by PCR 
band intensity from cDNA of patient samples. 
(Data: Sean Judge)  
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In my research, I have ectopically expressed DAX-1 in MCF7 cells to determine the effect of 
DAX-1 on target gene expression and proliferation rate in the context of breast cancer. 
Additionally, I employed RNA interference technologies using small interfering RNAs (siRNAs) 
to selectively knockdown the expression of DAX-1 in MCF10A normal breast cells. I have 
compared the expression level of target genes when DAX-1 was highly expressed in breast 
cancer cells and when DAX-1 levels were reduced in normal breast cells. By elucidating the 
targets affected by DAX-1 in breast cancer cells, as well as normal breast cells, we hope to gain a 
better understanding of the larger role this unique nuclear hormone receptor may play in cancer.  
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Chapter 2: Materials and Methods 
 
Cell Culture 
All cell lines were routinely passaged, cultured, and maintained at 37° C in a humidified 5% CO2 
tissue culture incubator. MCF7 human breast cancer cells were cultured in Dulbecco’s modified 
eagle medium (DMEM) or Ham’s F12 (1:1) without phenol red. Phenol red is an estrogen and 
since MCF7 cells are estrogen receptor positive cells they are sensitive to phenol red. Media was 
supplemented with 10% Fetal Bovine Serum (ATCC, Manassas, VA), 1% L-Glutamine 
(Invitrogen, Carlsbad, CA), 1% Penicillin/Steptomycin (Invitrogen, Carlsbad, CA), 1% 
Fungizone (Invitrogen, Carlsbad, CA), and Bovine Insulin (Sigma-Aldrich, St. Louis, MO).  
MCF10A human mammary epithelial cells were cultured in Dulbecco’s modified eagle medium 
(DMEM) or Ham’s F12 (1:1) without phenol red. Media was supplemented with 5% Horse 
Serum (ATCC, Manassas, VA), 1% L-Glutamine (Invitrogen, Carlsbad, CA), 1% 
Penicillin/Steptomycin (Invitrogen, Carlsbad, CA), 1% Fungizone (Invitrogen, Carlsbad, CA), 
and 100ng/ml cholera toxin (Sigma-Aldrich, Saint Louis, MO). MDA-MB-231 human triple 
negative breast cancer cells were cultured in Dulbecco’s modified eagle medium (DMEM) or 
Ham’s F12 (1:1) with phenol red and supplemented with 10% Fetal Bovine Serum (ATCC, 
Manassas, VA), 1% L-Glutamine (Invitrogen, Carlsbad, CA), 1% NEAA (Invitrogen, Carlsbad, 
CA), (1% Penicillin/Steptomycin (Invitrogen, Carlsbad, CA), and 1% Fungizone (Invitrogen, 
Carlsbad, CA).  
To passage and maintain cells, cells were first washed with phosphate buffered saline (PBS), 
treated with Trypsin-Versene (EDTA) and incubated at 37° C until released from flask. Cells 
were resuspended and passaged at a 1:8 ratio.  
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DNA Isolation  
Plasmid DNA was isolated using PureYield Plasmid Miniprep System (Promega, Madison, WI) 
according to the manufacturer's instructions using a starting volume of 2 mL of bacterial culture. 
Purified DNA was measured using the NanoDrop 1000 Spectrophotometer (Thermo Scientific, 
Wilmington, DE) and sequenced (McLab, South San Francisco, CA) to confirm DNA sequences.  
 
Viral Transfection  
Adenoviral vectors (BD Biosciences Clonetech, San Jose, CA) containing either the DAX-1 gene 
or the LacZ gene (control) were transfected into MCF7 and MDA-MB-231 cells. Cells were 
plated in six well plates in serum free media and transfected with 1µl of adenovirus containing 
either DAX-1 or LacZ per 1mL of media. Cells were incubated with virus in serum free media 
for 24 hours to synchronize cells to the same phase of the cell cycle. Cells were then treated with 
estrogen to a final concentration of 10-7 M for 1-72 hours. Cells were collected for total RNA 
isolation and cDNA was synthesized.  
 
Plasmid Transfection  
pcDNA 3.1 plasmid (Life Technologies, Carlsbad, CA) containing either the an empty vector 
control or the wild-type DAX-1 DNA sequence was transfected into MCF7 cells seeded in six 
cell plates using a range of concentrations (1500-2000ng) of plasmid with 50µL of Lafectine 
RU50 transfection reagent (MednaBio, Burlingame, CA). Cells were incubated for 48 hours and 
collected for total RNA isolation and whole cell protein lysate.  
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siRNA Transfection 
A set of three synthetic double stranded Stealth siRNA oligonucleotides targeting the DAX-1 
gene were obtained from Life Technologies (Carlsbad, CA) (Table 2-1). The medium GC non-
targeting Stealth oligonucleotide was used as a control. Six well plates were seeded at 500,000 
cells per cell and reverse transfected using Lafectine RU50 (MednaBio, Burlingame, CA) and 
300pmol concentration of control or targeting siRNAs. Cells were incubated for 48 hours and 
collected for total RNA isolation and whole cell protein lysate.  
 
siRNA Sequence  Target Region 
DAX-1 siRNA 1 CCCAUGACAGAUUCAUCGAACUUAA 
UUAAGUUCGAUGAAUCUGUCAUGGG 
Exon 2 
Position 1290 
DAX-1 siRNA 2 UCGGCACAGUCAGCAUGGAUGAUAU 
AUAUCAUCCAUGCUGACUGUGCCGA 
Exon 2 
Position 1383 
DAX-1 siRNA 3 CAGUGGCAGGGCAGCAUCCUCUACA 
UGUAGAGGAUGCUGCCCUGCCACUG 
Exon 1 
Position 44 
Table 2-1 siRNA sequences. 
 
 
RNA Isolation and cDNA Synthesis 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) as per the 
manufacturer's instruction, with the optional RNase-Free DNAse (Qiagen)  step added to remove 
genomic DNA contamination. RNA was measured for concentration and purity using the 
NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE). High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) was used to synthesize cDNA 
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from the isolated RNA according to manufacturer's instructions. Thermocycling was carried out 
using MJ Mini Personal ThermoCycler (BioRad, Hercules, CA) with the following conditions.  
 
 
 
Step 1 Step 2 Step 3 Step 4 
Temperature  25°C 37°C 85°C 4°C 
Time  10 min 120 min  5 min  ∞ 
Table 2-2 cDNA synthesis thermocycler conditions.  
 
cDNA was then measured via NanoDrop diluted and normalized for subsequent PCR analysis.  
 
Protein Isolation  
Whole cell protein lysate was collected following 24 or 48-hour treatments using either NP-40 or 
RIPA lysis buffer (Boston BioProducts, Worcester, MA) with Halt Protease Inhibitor (Thermo 
Fisher Scientific, Rockford, IL) added at a concentration of 1:100. Cells were trypsinized and 
collected from 6 well plates and centrifuged at 14,000 g for 5 minutes. Supernatant was removed 
and pelleted cells were resuspended in lysis buffer and incubated on ice for 15 minutes. Samples 
were sonicated using Misonix Ultrasonic Liquid Processor (Misonix, Inc, Farmingdale, NY) at 
an amplitude of 50 for two pulses of 30 seconds with a 40 second pause between pulses. The 
lysate was centrifuged at 14,000 g for 10 minutes to pellet insoluble materials and the 
supernatant was transferred to a new tube and stored at -70°C for future analysis.  
 
Western Blot  
Western blots were performed using the XCell II Blot Module (Invitrogen, Carlsbad, CA) 
according to the NuPAGE Novex Bis-Tris Protocol (Invitrogen, Carlsbad, CA) using 4X 
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NuPAGE LDS sample loading buffer and 10X NuPAGE sample reducing agent. Samples were 
normalized using the Coomassie Plus Bradford Protein Assay (Thermo Fisher Scientific, 
Rockford, IL) and then combined with sample loading buffer and reducing-agent to a final 
volume of 30µL. Samples were run on gradient 4-12% Bis-Tris SDS-PAGE gels for 45 minutes 
at 200V on the XCell II Blot Module. Protein was transferred from gel to PVDF membrane 
according to manufacturer’s protocol using XCell II Blot Module with blot apparatus. Transfer 
blots were run at 25V for 1 hour. Membranes were then blocked in 5% Blotto made in Tris-
Buffered Saline with Tween 20 (TBST) for 1 hour with rocking at 150 RPM and incubated 
overnight at 4° C with primary antibody (listed below) made in 5% Blotto at 1:1000 dilution 
with rocking at 150 RPM. Membranes were washed with TBST for 10 minutes three times 
before secondary antibody application. Appropriate secondary antibody, either rabbit or mouse 
(BD Biosciences, San Jose, CA) was prepared in 5% Blotto made with TBST at 1:2000 dilution. 
Membranes were incubated in secondary antibody for one hour at room temperature with 
rocking at 150 RPM, and then washed with TBST for 10 minutes three times prior to developing.  
Western blots were developed using the chemiluminescence Thermo Scientific Kit and analyzed 
using the BioRad GelDoc System (BioRad, Hercules, CA).    
 
Protein  Species  Company  
DAX-1 (K-17) Rabbit polyclonal Santa Cruz Biotech 
Santa Cruz, CA 
GAPDH Mouse monoclonal  Santa Cruz Biotech 
Santa Cruz, CA 
Cyclin D1 (N2C3) Rabbit polyclonal GeneTex 
Irvine, CA 
Table 2-3 Antibodies. 
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Standard PCR and qPCR 
cDNA made from extracted mRNA was used as template for standard PCR and qPCR. Samples 
for standard PCR were prepared using 12.5µL of 2X GoGreen (Promega, Madison, WI) or Taq 
2X Master Mix (New England BioLabs, Ipswich, MA), 0.25µL of 10μM	  forward and reverse 
primers (listed in table 2-5), 12µL of dH2O, and 2µL cDNA. PCR was performed using MJ Mini 
Personal ThermoCycler (BioRad, Hercules, CA) using the protocol below with varying 
annealing temperatures. 
 
 
 
Step Temp  Time 
Initial Denaturation  95° 4 minutes 
30 Cycles:  
Denaturation  
Annealing 
Elongation 
 
95°  
45-65° 
72° 
 
30 sec 
30 sec 
30 sec 
Final Extension 72° 4 minutes 
Hold 4° ∞ 
Table 2-4 PCR thermocycler conditions. 
 
 
Following PCR, samples were electrophoresed through a 1.5-2% 1X TAE agarose gel containing 
ethidium bromide. PCR products were visualized by ultraviolet light exposure using the BioRad 
GelDoc System (BioRad, Hercules, CA).    
 
qPCR reactions were performed in triplicate using BioRad CFX96 Real-Time PCR system. 
qPCR reactions were prepared using 10.5 µL of SYBR Green Master Mix (Life Technologies, 
Carlsbad, CA), 0.25µL of 10μM	  forward and reverse primers (listed in table 2-5), 12µL of dH2O, 
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and 2µL cDNA. GAPDH housekeeping gene was used as control and experimental genes were 
compared to GAPDH as a baseline. Fold-change values were calculated by comparing untreated 
and transfected samples. Error bars on qPCR results represent standard deviation of the mean. 
Statistical significance was calculated by using one and two tailed T-tests comparing untreated 
and transfected groups. Data found to be statistically significant (p< 0.05) is indicated by 
asterisks.  	  
Gene 
Name 
Fwd Primer 5’-3’ Rev Primer 5’-3’ Annealing 
Temp 
GAPDH ACA GCC GCA TCT TCT 
TGT GCA 
GGG CTT GAC TGT GCC 
GTT GAA 
58° C 
DAX-1  GAC TCC AGT GGG GAA 
CTC AG 
ATG ATG GGC CTG AAG 
AAC AG 
57° C 
CyclinD1 TAG CAC CTT GGA TGG 
GTA ATT 
 
ATC GTG CGG CAT TGC 
GGC 
 
 
59° C 
ERα CCA CCA ACC AGTT GCA 
CCA TT 
 
GCG AGT CTC CTT GGC 
AGA TCC 
 
54° C 
 
Ki-67 ACA GAC CTC AAG AGC 
TTG CC 
CCA GGG ATG CCT TCA 
ACT GT 
57° C 
MCM7 TGG CAC TGA AGG ACT 
ACG 
CTG AGG CAG CAG CTC 
TTG TA 
56° C 
TOP2A TGG GGT CCT GCC TGT 
TTA GT 
TGT CTG GGC GGA GCA 
AAA TA 
55° C 
Table 2-5 PCR Primers. 
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Cell Cycle Analysis  
MCF7 and MCF10A cells were grown in 6 well plates and transfected with either plasmids or 
siRNAs (previously described). Cells were collected and pelleted by centrifugation at 5,000 g for 
5 minutes, resuspended and washed in 500µL 1X PBS, and centrifuged at 5,000 g for 5 minutes. 
Supernatant was removed, cells were resuspended in 50µL PBS, and mixed with 500µL of 100% 
ethanol. Cells were stored overnight at -20°C. Cells were centrifuged at 5,000 g for 5 minutes 
and supernatant was removed. Cells were resuspended with 100 µL PI/RNase Staining Buffer 
(BD Pharmingen, San Diego, CA), 10µL Propidium Iodide Staining Solution (BD Biosciences, 
San Jose, CA) was added and incubated for 10 minutes before analysis by flow cytometry. The 
BD Acurri C6 (BD Biosciences, San Jose, CA) flow cytometer was used to analyze samples. 
Cell cycle analysis samples were run in duplicate. Statistical significance calculated by using two 
tailed T-test comparing untreated and transfected groups. Data found to be statistically 
significant (p< 0.05) is indicated by asterisks.  	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Chapter 2: Results  
 
Expression of DAX-1 in human breast adenocarcinoma cells (MCF7) by viral transfection.  
 A schematic of the workflow used for the following experiment is shown in Figure 2-2. 
MCF7 cells were serum-starved for 24 hours before being infected with control adenovirus 
containing the lacZ gene or adenovirus containing the DAX-1 gene (BD Biosciences Clonetech, 
San Jose, CA). After 24 hours exposure to virus, the cells were treated with estradiol (E2) to a 
final concentration of 10-7 M for a designated number of hours. After treatment with E2 cells 
were collected and total RNA was isolated and cDNA was synthesized. Finally, cDNA was 
analyzed using standard PCR.  
Considering the known repressional activity of DAX-1 on estrogen receptor and the role 
of ER in transcription of the cell cycle control protein, Cyclin D1, I wished to initially examine 
the effect of DAX-1 expression of Cyclin D1. It was found that the introduction of DAX-1 
expression into the MCF7 breast cancer cells resulted in a decrease in the amount of detectable 
ERα as well as Cyclin D1 (Figure 2-3). Since a decrease was seen in Cyclin D1, a key regulator 
of the progression from G1 into S phase of the cell cycle (Figure 2-4), I next wanted to determine 
if a change in proliferation level could be detected. Cell proliferation level was examined using a 
luciferase viability assay. Cells were transfected as described previously and treated with E2 for 
up to 72 hours. It was determined that the addition of DAX-1 not only decreased proliferation of 
MCF7 cells, but that cells regressed beyond the starting point (Figure 2-5 a). These data supports 
what was seen previously with the PCR expression data. A decrease in ERα and Cyclin D1 
expression should lead to a decrease in proliferation, since an ample concentration of Cyclin D1  
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Figure 2-2 Viral transfection workflow. 
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is required to propel cells from G1 to S phase. Reducing Cyclin D1 expression through an 
increase in DAX-1 level slowed proliferation of the MCF7 cells. 
To help confirm that the changes observed were due to repression of ERα by DAX-1, the 
proliferation assay was repeated in triple negative (ER, PR, and Her2 negative) breast cancer cell 
line (MDA-MB-231) that is epidermal growth factor (EGF) positive. The cells were transfected 
as before and treated with EGF for up to 120 hours. Some decrease in proliferation was observed 
in the DAX-1 treated cells, however the repression was much less striking compared to the ER 
positive MCF7 cells and cells did not regress beyond the starting number as was seen with the 
MCF7 cells (Figure 2-5 b). These findings help to support that the repression of proliferation 
seen in the MCF7 cells is largely due to DAX-1 inhibition of ERα activity. Without ERα, DAX-1 
has some effect on proliferation, but not to the same level seen in the ERα positive MCF7 cells.  
 
Expression of DAX-1 in human breast adenocarcinoma cells (MCF7) by plasmid transfection.  
To confirm the data previously observed in the MCF7 breast cancer cells using the 
adenoviral transfection technique, I utilized another non-viral transfection method. Since non-
viral transfection would later be used in RNA interference experiments, I used the same method 
for transfection of a plasmid containing the full-length wild-type DAX-1gene. Transfection of 
siRNAs required the use of lipid transfection, therefore the same transfection reagent was used to 
transfect DAX-1 and empty vector control plasmids. This would allow transfection conditions to 
be as similar as possible so that results could be more accurately compared between these two 
sets of experiments. 
 For these experiments cells were transfected with either an empty plasmid (vehicle 
control) or plasmid containing wild-type DAX-1 DNA sequence. MCF7 breast cancer cells were  
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Figure 2-3. PCR expression results following viral infection of DAX-1 into MCF7 cells.  
MCF7 cells were infected with LacZ (control) or DAX-1 containing adenovirus and treated with 
estrogen for up to 24 hours.  
DAX-1: DAX-1 cDNA level is increased. Confirmation of transfection, DAX-1 is detectable 
only in DAX-1 treated cells.  
ERα: ERα cDNA level is decreased with DAX-1 expression compared to LacZ control 
Cyclin D1: Cyclin D1 cDNA level is decreased with DAX-1 expression compared to LacZ 
control.   
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Figure 2-4. Cell cycle with cyclins. 
Movement through the cell cycle depends on the presence of cyclins, which work together with 
their specific kinase, or CDKs. Each phase of the cell cycle is mediated by different cyclins/CDK 
combinations. Cyclin D drives progression through G1 and into S phase. Cyclin E mediates the 
shift from G1 to S phase. Cyclin A drives progression through S phase and Cyclin B mediates 
the shift from G2 into the mitotic phase. (Image taken from: S. L. Forsburg, UCSD) 
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Figure 2-5a MCF7 ER positive cell proliferation assay. 
MCF7 cells were left untreated or infected with either control (LacZ) or DAX-1 adenovirus and 
treated with E2 for up to 72 hours. DAX-1 infected cells had slower rate of growth and 
proliferation. DAX-1 treated cells regress beyond starting number of cells.  
 
 
Figure 2-5b MDA-MB-231 ER negative cell proliferation assay. 
Cells were left untreated or infetced with either control (LacZ) or DAX-1 adenovirus and treated 
with EGF for up to 120 hours. DAX-1 infected cells had a somewhat slower rate of growth and 
proliferation, but cells did not regress as with MCF7 cells.  
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plated and reverse transfected. Following transfection, cells were incubated for 48 hours, 
collected, and prepped for either mRNA isolation or protein lysis. 
Expression levels of GAPDH (control housekeeping gene), DAX-1, and Cyclin D1 were 
examined by PCR and western blot (Figure 2-6 a and b). Successful transfection was confirmed 
by detection of DAX-1. As shown in Figure 2-6, an increase in the amout of DAX-1 was 
observed in the cells transfected with wild-type DAX-1 when compared to the untreated or 
empty vector control cells (lanes 1-3). When the amount of DAX-1 was increased, a significant 
decrease in the amount of Cyclin D1 was detected by standard PCR. This was confirmed by 
western blot, where the amount of Cyclin D1 protein was decreased upon DAX-1 introduction 
into cells. Quantitative PCR was performed to measure the change in expression of these two 
gene targets as well as estrogen receptor alpha (ERα). Using GAPDH as a reference, a 4.8 fold 
upregulation in the amount of DAX-1 cDNA (p= .007) and a 7.9 fold downregulation in the 
amount of Cyclin D1 cDNA (p= .004) was detected (Figure 2-7) upon DAX-1 introduction into 
MCF7 cells.  
 To determine if the decrease in Cyclin D1 observed had any effect on proliferation of the 
MCF7 cells, downstream proliferation targets were analyzed. Three specific S phase genes were 
chosen; Ki-67, MCM7, and TOP2A. Ki-67 is a nonhistone nuclear antigen and a classic 
proliferation marker. Proliferating cells have higher levels of Ki-67 than do cells that are in arrest 
or quiescent. Minichromosomal maintance complex component 7 (MCM7) is a protein that is 
essential for initiating genome replication and is involved in the formation of replication forks. 
Topoisomerase II alpha (TOP2A) is an enzyme that helps to change topological states of DNA 
during replication. TOP2A is involved in chromatid condensation, separation, and creating nicks  
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Figure 2-6 Target gene cDNA and protein levels in DAX-1 transfected MCF7 cells. 
cDNA (left) and protein (right) levels of GAPDH (control), DAX-1, and Cyclin D1 for 
transfected MCF7 breast cancer cells. When DAX-1 is expressed in MCF7 cells Cyclin D1 
expression levels decrease. UT: untreated, LO: lipid transfection reagent only, p-DAX-1: WT 
DAX-1 plasmid.  
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Figure 2-7 qPCR expression of DAX-1 and Cyclin D1 for DAX-1 transfected MCF7 cells.  
Increased DAX-1 expression by transfection of WT DAX-1 (pCDNA3.1-DAX1) results in a 
reduction in Cyclin D1 expression level when compared to untreated cell (UT).  
 P<0.05 *  
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in the DNA to help relieve torsional stress during DNA synthesis.  These genes were chosen 
because they code for proteins that function and are increased during DNA sythesis. 
 Since DAX-1 has been shown to cause a reduction in Cyclin D1 levels, we hypothesize that 
fewer cells would be moving from G1 into S phase and undergoing DNA synthesis. 
 Results from qPCR data show a decrease in the three S phase genes upon DAX-1 
treatment compared to untreated or vehicle control cells (Figure 2-8). Decreases in MCM7 and 
TOP2A were found to be statistically significant, p= .05 and p= .03 respectively. This data 
indicates that reduction of Cyclin D1 via DAX-1 repression of ERα caused cells to remain in G1 
phase rather than progress to S phase, and as a result have a lower level of expression of the three 
S phase markers.  
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Figure 2-8 qPCR analysis of proliferation gene targets. 
qPCR expression for MCF7 breast cancer cells  untreated (UT) or WT DAX-1 plasmid 
(pcDNA3.1-DAX1). Increased DAX-1 expression (4.8 fold) caused a decrease in expression of 
Cyclin D1 (-3.3 fold), Ki-67 (-1.7 fold), ERα (-1.56 fold), MCM7 (-2.2 fold), and TOP2A (-1.6 
fold). P<0.05 *  
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Knockdown of DAX-1 in human epithelial breast cells (MCF10A) by siRNA transfection. 
Following detection of the anti-proliferative effects of expressing DAX-1 in the MCF7 
breast cancer cells, I wished to address whether knockdown of DAX-1 expression via RNA 
interference (RNAi) in normal breast cells would give the opposite effect. A combination of 
three DAX-1 targeting small interfering RNAs (Life Technologies) was used to reduce 
expression of DAX-1. This technique takes advantage of an intrinsic molecular mechanism that 
allows for the specific targeting of an mRNA within the cell. RNAi results in a decrease in the 
number of transcripts present for the gene being targeted.  Reducing the number of mRNA 
transcripts leads to decreased protein expression of the targeted gene. Using siRNA targeted 
towards DAX-1 provided a means to analyze downstream targets affected by the presence or 
reduction of DAX-1.  
Normal human epithelial breast cells (MCF10A) were used as the model for these experiments as 
these cells are ER negative, but express DAX-1. Cells were plated and reverse transfected with 
either the pool of three DAX-1 targeting siRNAs or a control siRNA. Cells were collected after 
48 hours of incubation and either mRNA isolation or whole cell protein lysate was prepared. 
Samples were analyzed by standard PCR, qPCR, and western blot for GAPDH (control), DAX-
1, and Cyclin D1 expression (Figure 2-9). Knockdown of DAX-1 was confirmed visually with 
PCR and western blot as well as quantitatively by qPCR (Figure 2-10). When compared with the 
GAPDH control, a range from 4 to 8-fold decrease in DAX-1 levels was observed following 
treatment with DAX-1 targeting siRNA. 
Once knockdown had been confirmed, Cyclin D1 levels were analyzed by PCR, qPCR, 
and western blot. As hypothesized, Cyclin D1 levels increased when the DAX-1 level was  
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Figure 2-9 cDNA and protein levels following DAX-1 knockdown in MCF10A cells. 
cDNA (left) and protein (right) levels of GAPDH (control), DAX-1, and Cyclin D1 for siRNA 
transfected MCF10A normal breast cells. UT: untreated, LO: lipid transfection reagent only, si-
DAX-1: set of three DAX-1 targeting siRNAs. When DAX-1 expression levels decrease, Cyclin 
D1 expression levels were shown to increase. 
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Figure 2-10 qPCR analysis of DAX-1 and Cyclin D1 following DAX-1 knockdown in 
MCF10A cells.  
When DAX-1 expression level is reduced by siRNAs, Cyclin D1 expression levels increase.  
P<0.05 *  
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reduced (Figure 2-9 and 2-10). It was found by qPCR that DAX-1 decreased by a 6.2 fold-
change (p= .005) and Cyclin D1 increased by a 3.1 fold-change (p= 0.002) when compared to 
untreated cells. S phase proliferation markers Ki67, MCM7, and TOP2A were analyzed by qPCR 
and were found to be significantly increased when compared to untreated and control cells 
(Figure 2-11).  These results confirm the role of DAX-1 in slowing proliferation by repression of 
Cyclin D1 gene expression. 
 
Cell cycle analysis of DAX-1 transfected MCF7 cells and DAX-1 knockdown MCF10A cells.  
 Cell cycle analysis is a way to determine what stage of the cell cycle a population of cells 
is in using propidium iodide (PI) staining of DNA (Figure 2-12). The amount of staining makes 
it possible to differentiate between cells in G0/G1, S phase, and G2/M phase. Cells in G2/M 
phase will have twice the amount of DNA as cells in G0/G1 and therefore twice the amount of 
signal from PI staining.   
MCF7 breast cancer cells were transfected with either empty vector (plasmid only 
control) or a plasmid containing wild-type DAX-1. Concurrently, MCF10A normal breast cells 
were transfected with non-targeting control or DAX-1 targeting siRNAs. In both cases cells were 
incubated for 48 hours and collected. Collected cells were permeablized over-night with ethanol, 
stained with PI, and analyzed by flow cytometry. In the MCF7 breast cancer cells, there was a 
shift in the cells transfected with the DAX-1 plasmid. Specifically, more cells were in G0/G1 
compared with the untreated or vehicle control transfected cells (Figure 2-13a). In the untreated 
cells and vehicle control cells, 30% and 30.2% respectively of the total cells were in G0/G1 
phase, whereas in the DAX-1 transfected cells 40.3% of cells were in G0/G1 (Figure 2-13b). 
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Figure 2-11 qPCR analysis of proliferation target genes. 
 qPCR expression for MCF10A normal breast cells that were either untreated (UT) or transfected 
with a set of three DAX-1 targeting siRNAs (si-DAX-1). DAX-1 knockdown (-3.6 fold) caused 
an increase in Cyclin D1 (3.9 fold) , Ki-67 (2.2 fold), MCM7 (3.4 fold), and TOP2A (1.7 fold).  
MCF10A cells are ER negative, therefore ER levels did not change when DAX-1 was knocked 
down by siRNA. 
P<0.05 * 
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Figure 2-12 Cell cycle analysis diagram. 
Peaks on histogram represent different stages of the cell cycle. Apoptotic cells are represented by 
the initial segment of the histogram, the first peak represents cells in G0/G1 (diploid 
chromosome content), the valley between peak one and two are cells in S-phase (somewhere 
between diploid and double diploid chromosome content), and the second peak represents cells 
in G2/M phase (double diploid chromosome content, ready to divide).  
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In the normal breast MCF10A cells there was a shift in the opposite direction when 
DAX-1 was knocked down by siRNA (Figure 2-14a). Untreated and non-targeting control 
siRNA treated samples had 51.1% and 47.7% of cells in G0/G1 compared to 42.5% of cells in 
G0/G1 for the DAX-1 knockdown cells (Figure 2-14b). These data help to support the 
hypothesis that DAX-1 functions as a repressor of growth and slows progression through the cell 
cycle. Not only is DAX-1 reducing the amount of Cyclin D1, but this reduction has downstream 
effects on both S phase genes as well as the rate of cells moving through the cell cycle as 
demonstrated by cell cycle analysis. 
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Figure 2-13a Cell cycle analysis for transfected MCF7 cells.  
First peak in histogram represents proportion of cells in G0/G1 phase of cell cycle, second peak 
represents cells in G2/M phase of cell cycle. A greater proportion of cells transfected with DAX-
1 were found in G0/G1 compared to untreated and control cells.  
UT: untreated VC: vehicle control WT: wild-type DAX-1. 
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Figure 2-13b Quantification of cells in each phase of the cell cycle after transfection with 
DAX-1.  
G0/G1 phase: Vehicle: 30.2% Wild-type DAX-1(pCDNA3.1-DAX1): 40.3%, S phase: Vehicle: 
8.8% Wild-type DAX-1(pCDNA3.1-DAX1): 11.1%, G2/M phase: Vehicle:15.3% Wild-type 
DAX-1(pCDNA3.1-DAX1): 12.4% 
Expression of DAX-1 leads to a greater percentage of cells remaining in G0/G1. 
P<0.05 *  
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Figure 2-14a Cell cycle analysis of DAX-1 knockdown MCF10A cells. 
First peak in histogram represents proportion of cells in G0/G1 phase of cell cycle, second peak 
represents cells in G2/M phase of cell cycle. DAX-1 knockdown cells (SI) have fewer cells in 
G0/G1 compared to untreated and control cells.  
UT: untreated NT: non-targeting control siRNA siDAX: DAX-1 targeting siRNA.  
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Figure 2-14b Quantification of cells in each phase of the cell cycle. 
G0/G1 phase: Non-targeting siRNA control (si-NT): 47.7% DAX-1 targeting siRNA (si-DAX-
1): 42.5%, S phase: Non-targeting siRNA control (si-NT): 9.3% DAX-1 targeting siRNA (si-
DAX-1): 6.5%, G2/M phase: Non-targeting siRNA control (si-NT): 19.4% DAX-1 targeting 
siRNA (si-DAX-1): 20.0% 
Knockdown of DAX-1 leads to fewer cells in G0/G1 and an increase of cells entering the cell 
cycle.  
P<0.05 *  
 
 
 
 
  
47.7 
6.5 
20 
42.5 
9.3 
19.4 
0 
10 
20 
30 
40 
50 
60 
GO/G1 S G2/M 
Pe
rc
en
ta
ge
 o
f C
el
ls
 in
 E
ac
h 
Ph
as
e 
Phase of the Cell Cycle  
NT 
SI-DAX1 *	  
*	  
	  	   62	  
Chapter 2: Discussion and Future Directions 
 
 DAX-1 has been shown to act as a repressor of transcriptional activity for several nuclear 
hormone receptors [18, 40, 45]. This research aimed to explore known DAX-1 target genes, such 
as the NHR estrogen receptor alpha and its gene target Cyclin D1, as well as to identify 
additional proliferation targets affected by DAX-1 expression. By examining the effects of 
increasing DAX-1 expression in DAX-1 deficient cells as well as reducing expression of DAX-1 
by siRNA knockdown in DAX-1 positive cells, it was determined that DAX-1 plays an 
important role in moderating proliferation. It is thought that DAX-1 exerts its repressive activity 
primarily through transcriptional inhibition of ERα. Repression of ERα prevents transcription of 
Cyclin D1, thereby preventing cells from transitioning into the G1 phase of the cell cycle. This 
was observed both by gene expression data as well as by proliferation assay and cell cycle 
analysis. A decrease in expression of three proliferation genes, Ki-67, MCM7, and TOP2A was 
observed in cells transfected with a DAX-1 expression plasmid. These three genes are not 
believed to be direct targets of DAX-1, rather their reduced expression is likely a consequence of 
DAX-1 inhibited progression through G1 phase of the cell cycle. Ki-67, MCM7, and TOP2A are 
markers connected with later stages of the cell cycle, therefore are not expressed when DAX-1 is 
present and causes a reduction in cell cycle progression.  
Support of the expression data for DAX-1 transfected cells was reinforced by a viability 
proliferation assay demonstrating that MCF7 DAX-1 deficient cells transfected with a DAX-1 
expression plasmid had reduced proliferation compared to untreated cells. Cells transfected with 
DAX-1 even regressed beyond the starting number of cells, indicating that DAX-1 may also play 
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some role in promoting apoptosis. Experiments exploring the possible role of DAX-1 in 
promoting apoptosis are currently being researched in the Tzagarakis-Foster lab.   
From the results observed in the DAX-1 transfection experiments, it was hypothesized 
that knockdown of DAX-1 in DAX-1 positive MCF10A cells would lead to the opposite effect 
and an increase of proliferative gene targets would result. This hypothesis was supported by 
expression data. Expression levels of Cyclin D1, Ki-67, MCM7, and TOP2A were all found to 
increase when DAX-1 was knocked down in MCF10A cells.  This cell line is ERα negative, 
indicating that aside from this known target, DAX-1 must be able to act through another gene 
target. Determination of this mechanism of repression is the subject of ongoing research in the 
Tzagarakis-Foster Lab and may tie in to the hypothesis that DAX-1 is not only involved in 
proliferation, but that it may also play a role in apoptosis.    
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Chapter 3: Determining the SUMOylation status and effects of SUMOylation on 
DAX-1 
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Chapter 3: Introduction  
 
SUMOylation involves the post-translational addition of one or more SUMO (small 
ubiquitin-related modifier) peptides to target proteins. The SUMO gene (SMT3) was first 
discovered in the mid 1990’s and was originally identified in Saccharomyces cerevisae. SUMO 
was later observed as a binding partner for the human proteins RAD51, RAD52, and FAS [46-
48]. RAD51 and RAD52 are important proteins for the repair of double stranded breaks in DNA, 
whereas FAS is known as the death receptor and plays an important role in the extrinsic 
apoptosis pathway. The interaction that solidified SUMO as an interesting and important protein 
was the discovery of SUMO covalently attached to Ran GTPase-activating protein 
(RanGAP1)[49]. This was of particular significance because unmodified RanGAP1 is only found 
in the cytosol, whereas SUMOylated RanGAP1 is found in the nucleus [49, 50]. This discovery 
helped to define two key characteristics of SUMO and the effects of SUMOylation: 
SUMOylation is a reversible and dynamic post-translational modification, and SUMOylation can 
alter the localization of proteins by changing protein interactions [51].   
SUMO proteins are expressed in all eukaryotes. Although some organisms have only a 
single SUMO protein, humans have been found to express four different SUMO proteins 
(SUMO 1-4) [52].  In humans SUMO1-SUMO3 are expressed ubiquitously, wereas SUMO4 is 
expressed more selectively in the lymph nodes, spleen, and kidneys [53]. The four SUMO 
proteins are approximately 10 kDa in size and though they resemble ubiquitins in structure, they 
share only 20% amino acid sequence identity [51]. SUMO2 and SUMO3 are very similar at 97% 
sequence identity, but share only 50% amino acid sequence identity with SUMO1 [54]. The 
functions of SUMOs appear to be distinct as the different types of SUMO are often conjugated to 
different proteins in vivo [55, 56].  The role of SUMO4 is still unclear [53].  
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SUMOylation occurs at specific consensus binding sites within a target protein. The 
SUMO-acceptor site has been shown to be ΨKxE, where Ψ is a branched hydrophobic amino 
acid, K is a lysine reside, x is any amino acid, and E is a glutamic acid [57]. The lysine residue is 
the actual site of attachment of the SUMO protein.  
In the past decade the enzymes involved in SUMOylation have been identified, as have 
numerous SUMO targets, many of which are nuclear proteins. The reversible mechanism of 
SUMOylation involves three classes of enzymes: E1 activating enzymes, E2 conjugating 
enzymes, and E3 ligating enzymes. Mature SUMO proteins are first activated with an E1 
activating enzyme heterodimer AOS1-UBA2. This reaction results in a thioester bond formation 
between the C-terminal carboxyl group of SUMO and the catalytic cysteine residue of UBA2 
[58, 59]. After activation, SUMO is conjugated to E2 activating enzyme UBC9 via another 
thioester bond with a cysteine residue on UBC9 [60, 61]. SUMO is then ligated to target proteins 
via an isopeptide bond formed between the C-terminal glycine on SUMO and a lysine residue of 
the target protein [62, 63]. This ligation step is carried out by E3 ligases that transfer SUMO 
from UBC9 onto the target. There are a number of ligases that can carry out this final step in the 
SUMOylation process, including members of the protein inhibitor of activated STAT (PIAS) 
family of enzymes [62-64].  Most often a single SUMO protein is added to a target, however 
polySUMO chains have been seen with SUMO2/3 [61]. 
Removal of SUMOylation from a target protein occurs via a number of different 
proteases.  Three different isopeptidases observed to carry out deSUMOylation are the sentrin-
specific proteases (SENP1-3, SENP5-7), SUMO-specific protease (SUSP1), and ubiquitin-like 
protease (Ulp) [51, 57]. The SENP family of enzymes is responsible not only for the cleavage of 
SUMO from target proteins, but also for the hydrolysis of newly synthesized SUMO proteins to 
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their mature form [65].  SUMO proteins are synthesized with a variable C-terminal stretch of 2-
11 amino acids that follows a conserved glycine-glycine motif; this is the region that is cleaved 
to form the mature SUMO protein [54]. The C-terminal glycine-glycine region is where SUMO 
attachment to lysine residues in the target protein occurs.  
SUMOylation has been identified on many protein targets including transcription factors, 
cofactors, and coregulators [57]. The addition of SUMO to transcription factors tends to result in 
a decrease in transcriptional activity and an overall reduction in gene expression [66]. 
SUMOylation sites have been identified on a number of nuclear hormone receptors including 
progesterone receptor, estrogen receptor, androgen receptor, and steroidogenic factor 1 (SF-1) 
[67-69]. SF-1, a close relative of DAX-1, is responsible for normal endocrine tissue development 
and regulation of reproductive and stress endocrine signaling axes. When SF-1 SUMOylation 
sites were eliminated by knock-in mouse models, mice developed smaller adrenal glands and had 
numerous abnormalities in development of the gonads, all of which led to infertility in both 
males and females [69]. These knock-in SUMO mutants also exhibited changes in normal 
hedgehog signaling patterns. In wild-type mice, desert hedgehog (Dhh) expression is present in 
the testes and sonic hedgehog (Shh) is absent. However in the SUMO mutant mice, Shh 
expression was detectable and Dhh expression was reduced [69]. The striking changes observed 
with mutation of SUMO sites within SF-1 led to the hypothesis that DAX-1 may also be 
SUMOylated and that mutation of DAX-1 SUMO sites may lead to changes in activity or 
function of DAX-1.  
In my research, I have determined the SUMOylation status of DAX-1 and explored the 
effects of SUMOylation on DAX-1 by mutating putative SUMO sites within the DAX-1 gene. 
Wild-type and DAX-1 SUMO mutants were transfected into MCF7 cells to compare differential 
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expression of target genes. Effects of SUMOylation on cell cycle progression and apoptosis were 
also examined. By determining the SUMOylation status and effects of SUMOylation on DAX-1, 
we hope to gain a better understanding of how this post-translational modification alters the 
function of DAX-1.   
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Chapter	  3:	  Materials	  and	  Methods	  	  Cell	  Culture	  All	  cell	  lines	  were	  routinely	  passaged,	  cultured,	  and	  maintained	  at	  37°	  C	  in	  a	  humidified	  5%	  CO2	  tissue	  culture	  incubator	  as	  described	  in	  Chapter	  2.	  MCF7	  human	  breast	  cancer	  cells	  and	  MCF10A	  normal	  breast	  cells	  were	  cultured	  as	  described	  in	  Chapter	  2.	  SW13	  human	  adrenal	  carcinoma	  cells,	  MDA-­‐MB-­‐231	  human	  triple	  negative	  breast	  cancer	  cells,	  and	  A549	  human	  lung	  carcinoma	  cells	  were	  cultured	  in	  Dulbecco’s	  modified	  eagle	  medium	  (DMEM)	  and	  Ham’s	  F12	  (1:1)	  with	  phenol	  red	  and	  supplemented	  with	  10%	  Fetal	  Bovine	  Serum	  (ATCC,	  Manassas,	  VA),	  1%	  L-­‐Glutamine	  (Invitrogen,	  Carlsbad,	  CA),	  1%	  NEAA	  (Invitrogen,	  Carlsbad,	  CA),	  (1%	  Penicillin/Steptomycin	  (Invitrogen,	  Carlsbad,	  CA),	  and	  1%	  Fungizone	  (Invitrogen,	  Carlsbad,	  CA).	  	  	  DNA	  Isolation	  	  Plasmid	  DNA	  was	  isolated	  using	  PureYield	  Plasmid	  Miniprep	  System	  (Promega,	  Madison,	  WI)	  according	  to	  the	  manufacturer's	  instructions	  using	  a	  starting	  volume	  of	  2	  mL	  of	  bacterial	  culture.	  Purified	  DNA	  was	  measured	  using	  the	  NanoDrop	  1000	  Spectrophotometer	  (Thermo	  Scientific,	  Wilmington,	  DE)	  and	  sequenced	  (McLab,	  South	  San	  Francisco,	  CA)	  to	  confirm	  DNA	  sequences.	  	  	  RNA	  Isolation	  and	  cDNA	  Synthesis	  Total	  RNA	  was	  isolated	  using	  the	  RNeasy	  Mini	  Kit	  (Qiagen,	  Valencia,	  CA)	  as	  per	  the	  manufacturer's	  instruction,	  with	  the	  optional	  RNase-­‐Free	  DNAse	  (Qiagen)	  	  step	  added	  to	  remove	  genomic	  DNA	  contamination.	  RNA	  was	  measured	  for	  concentration	  and	  purity	  using	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the	  NanoDrop	  1000	  Spectrophotometer	  (Thermo	  Scientific,	  Wilmington,	  DE).	  High	  Capacity	  cDNA	  Reverse	  Transcription	  Kit	  (Applied	  Biosystems,	  Foster	  City,	  CA)	  was	  used	  to	  make	  cDNA	  with	  isolated	  RNA	  according	  to	  manufacturer's	  instructions.	  Thermocycling	  was	  carried	  out	  using	  MJ	  Mini	  Personal	  ThermoCycler	  (BioRad,	  Hercules,	  CA)	  with	  the	  following	  conditions.	  	  	  
	  	   Step	  1	   Step	  2	   Step	  3	   Step	  4	  
Temperature	  	   25°C	   37°C	   85°C	   4°C	  
Time	  	   10	  min	   120	  min	  	   5	  min	  	   ∞	  
Table	  3-­‐1	  cDNA	  synthesis	  thermocycler	  conditions.	  	  
	  cDNA	  was	  then	  measured	  via	  NanoDrop,	  diluted,	  and	  normalized	  for	  subsequent	  PCR	  analysis.	  	  	  Plasmid	  Transfection	  	  pcDNA	  3.1	  plasmid	  (Life	  Technologies,	  Carlsbad,	  CA)	  containing	  no	  insert,	  wild-­‐type	  DAX-­‐1	  or	  SUMO	  DAX-­‐1	  mutant	  DNA	  sequences	  were	  transfected	  into	  MCF7	  cells	  seeded	  in	  six	  cell	  plates	  using	  a	  range	  of	  concentrations	  (1500-­‐2000ng)	  of	  plasmid	  with	  50μL	  of	  Lafectine	  RU50	  transfection	  reagent	  (MednaBio,	  Burlingame,	  CA).	  Cells	  were	  incubated	  for	  48	  hours	  and	  then	  collected	  for	  total	  RNA	  isolation	  and	  whole	  cell	  protein	  lysate.	  	  	  Protein	  Isolation	  Whole	  cell	  protein	  lysate	  was	  collected	  following	  24	  or	  48-­‐hour	  treatments	  using	  either	  NP-­‐40	  or	  RIPA	  lysis	  buffer	  (Boston	  BioProducts,	  Worcester,	  MA)	  with	  Halt	  Protease	  Inhibitor	  (Thermo	  Fisher	  Scientific,	  Rockford,	  IL)	  added	  at	  a	  concentration	  of	  1:100.	  Cells	  were	  collected	  from	  6	  well	  plates	  and	  centrifuged	  at	  14,000	  g	  for	  5	  minutes.	  Supernatant	  was	  removed	  and	  pelleted	  cells	  were	  resuspended	  in	  lysis	  buffer	  and	  incubated	  on	  ice	  for	  15	  minutes.	  Samples	  were	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sonicated	  at	  an	  amplitude	  of	  50	  for	  two	  pulses	  of	  30	  seconds	  with	  a	  40	  second	  pause	  between	  pulses.	  The	  lysate	  was	  centrifuged	  at	  14,000	  g	  for	  10	  minutes	  to	  pellet	  insoluble	  materials	  and	  the	  supernatant	  was	  transferred	  to	  a	  new	  tube	  and	  stored	  at	  -­‐70°C	  for	  future	  analysis.	  	  	  Western	  Blot	  	  Western	  blots	  were	  performed	  using	  the	  XCell	  II	  Blot	  Module	  (Invitrogen,	  Carlsbad,	  CA)	  according	  to	  the	  NuPAGE	  Novex	  Bis-­‐Tris	  Protocol	  (Invitrogen,	  Carlsbad,	  CA)	  using	  4X	  NuPAGE	  LDS	  sample	  loading	  buffer	  and	  10X	  NuPAGE	  sample	  reducing	  agent.	  Samples	  were	  normalized	  using	  the	  Coomassie	  Plus	  Bradford	  Protein	  Assay	  (Thermo	  Fisher	  Scientific,	  Rockford,	  IL)	  and	  then	  combined	  with	  sample	  loading	  buffer	  and	  reducing-­‐agent	  to	  a	  final	  volume	  of	  30uL.	  Samples	  were	  electrophoresed	  through	  gradient	  4-­‐12%	  Bis-­‐Tris	  SDS-­‐PAGE	  gels	  for	  45	  minutes	  at	  200V	  on	  the	  XCell	  II	  Blot	  Module.	  Protein	  was	  transferred	  from	  gel	  to	  PVDF	  membrane	  according	  to	  manufacturer’s	  protocol	  using	  XCell	  II	  Blot	  Module	  with	  Blot	  apparatus.	  Blots	  were	  transferred	  at	  25V	  for	  1	  hour.	  Membranes	  were	  then	  blocked	  at	  room	  temperature	  in	  5%	  Blotto	  made	  in	  1X	  Tris-­‐Buffered	  Saline	  with	  0.5%	  Tween	  20	  (TBST)	  for	  1	  hour	  with	  rocking	  at	  150	  RPM	  and	  incubated	  overnight	  at	  4°	  C	  with	  primary	  antibody	  (listed	  below)	  made	  in	  5%	  Blotto	  at	  1:1000	  dilution	  with	  rocking	  at	  150	  RPM.	  	  	  Western	  blots	  were	  developed	  using	  the	  chemiluminescence	  Thermo	  Scientific	  Kit	  and	  analyzed	  using	  the	  BioRad	  GelDoc	  System	  (BioRad,	  Hercules,	  CA).	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Protein	  	   Species	   Company	  DAX-­‐1	  (K-­‐17)	   Rabbit	  polyclonal	   Santa	  Cruz	  Biotech	  Santa	  Cruz,	  CA	  DAX-­‐1	   Mouse	  monoclonal	   Active	  Motif	  Carlsbad,	  CA	  GAPDH	   Mouse	  monoclonal	  	   Santa	  Cruz	  Biotech	  Santa	  Cruz,	  CA	  SUMO-­‐1	  (C9H1)	   Rabbit	  monoclonal	  	   Cell	  Signaling	  Technologies	  Danvers,	  MA	  SUMO-­‐2/3	  (I8H8)	   Rabbit	  monoclonal	  	   Cell	  Signaling	  Technologies	  Danvers,	  MA	  
Table	  3-­‐2	  Antibodies.	  	  
	  Standard	  PCR	  and	  qPCR	  cDNA	  was	  synthesized	  from	  extracted	  mRNA	  and	  was	  used	  as	  template	  for	  standard	  PCR	  and	  qPCR.	  Samples	  for	  standard	  PCR	  were	  prepared	  using	  11μL	  of	  2X	  GoGreen	  (Promega,	  Madison,	  WI)	  or	  Taq	  2X	  Master	  Mix	  (New	  England	  BioLabs,	  Ipswich,	  MA),	  0.25μL	  of	  10μM	  forward	  and	  reverse	  primers	  (listed	  in	  Table	  3-­‐4)	  ,	  12μL	  of	  dH2O,	  and	  2μL	  cDNA.	  PCR	  was	  performed	  using	  MJ	  Mini	  Personal	  ThermoCycler	  (BioRad,	  Hercules,	  CA)	  using	  the	  protocol	  below	  with	  varying	  annealing	  temperatures.	  	  	  
Step	   Temp	  	   Time	  Initial	  Denaturation	  	   95°	   4	  minutes	  30	  Cycles:	  	  Denaturation	  	  Annealing	  Elongation	  
	  95°	  	  45-­‐65°	  72°	  
	  30	  sec	  30	  sec	  30	  sec	  Final	  Extension	   72°	   4	  minutes	  Hold	   4°	   ∞	  
Table	  3-­‐3	  PCR	  thermocycler	  conditions.	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Following	  PCR,	  samples	  were	  electrophoresed	  through	  a	  1.5-­‐2%	  1X	  TAE	  agarose	  gel	  containing	  ethidium	  bromide.	  PCR	  products	  were	  visualized	  by	  ultraviolet	  light	  exposure	  using	  the	  BioRad	  GelDoc	  System	  (BioRad,	  Hercules,	  CA).	  	  	  	  
qPCR reactions were performed in triplicate using BioRad CFX96 Real-Time PCR system. 
qPCR reactions were prepared using 10.5 µL of SYBR Green Master Mix (Life Technologies, 
Carlsbad, CA), 0.25µL of 10μM	  forward and reverse primers (listed in table 2-5), 12µL of dH2O, 
and 2µL cDNA. GAPDH housekeeping gene was used as control and experimental genes were 
compared to GAPDH as a baseline. Fold-change values were calculated by comparing untreated 
and transfected samples. Error bars on qPCR results represent standard deviation (positive error) 
and standard error (negative error). Statistical significance of qPCR data is indicated on graphs 
by asterisks: P<0.05 * P<0.01 ** P<0.005 ***. 
 
Gene	  
Name	   Fwd	  Primer	  (5’-­‐3’)	   Rev	  Primer	  (5’-­‐3’)	   Annealing	  Temp	  GAPDH	   ACA	  GCC	  GCA	  TCT	  TCT	  TGT	  GCA	   GGG	  CTT	  GAC	  TGT	  GCC	  GTT	  GAA	   58°	  C	  DAX-­‐1	  	   GAC	  TCC	  AGT	  GGG	  GAA	  CTC	  AG	   ATG	  ATG	  GGC	  CTG	  AAG	  AAC	  AG	   57°	  C	  CyclinD1	   TAG	  CAC	  CTT	  GGA	  TGG	  GTA	  ATT	  	   ATC	  GTG	  CGG	  CAT	  TGC	  GGC	  	   	  59°	  C	  ERα	   CCA	  CCA	  ACC	  AGTT	  GCA	  CCA	  TT	  	   GCG	  AGT	  CTC	  CTT	  GGC	  AGA	  TCC	  	   54°	  C	  	  Ki-­‐67	   ACA	  GAC	  CTC	  AAG	  AGC	  TTG	  CC	   CCA	  GGG	  ATG	  CCT	  TCA	  ACT	  GT	   57°	  C	  MCM7	   TGG	  CAC	  TGA	  AGG	  ACT	  ACG	   CTG	  AGG	  CAG	  CAG	  CTC	  TTG	  TA	   56°	  C	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TOP2A	   TGG	  GGT	  CCT	  GCC	  TGT	  TTA	  GT	   TGT	  CTG	  GGC	  GGA	  GCA	  AAA	  TA	   55°	  C	  
Table 3-4 PCR primers. 
 	  PCR	  Mutagenesis	  DAX-­‐1	  SUMO	  mutants	  were	  constructed	  using	  the	  QuikChange	  Lightning	  Site-­‐Directed	  Mutagnesis	  Kit	  (Agilent	  Technologies,	  La	  Jolla,	  CA).	  Primers	  were	  designed	  to	  mutate	  lysine	  residues	  at	  positions	  249	  and	  362	  within	  the	  DAX-­‐1	  amino	  acid	  sequence	  (Table	  3-­‐5).	  Mutagenesis	  primers	  and	  pcDNA	  3.1	  plasmid	  (Life	  Technologies,	  Carlsbad,	  CA)	  containing	  the	  wild-­‐type	  DAX-­‐1	  sequence	  were	  used	  along	  with	  the	  QuikChange	  Lightning	  Site-­‐Directed	  Mutagnesis	  Kit	  as	  per	  the	  manufacture’s	  protocol.	  Following	  PCR	  mutagenesis,	  the	  resulting	  product	  was	  digested	  with	  methylation-­‐specific	  restriction	  endonuclease	  Dpn1,	  allowing	  for	  the	  digestion	  of	  parental	  plasmid	  only.	  Nascent	  plasmids	  were	  transformed	  into	  XL10-­‐Gold	  Ultracompetent	  bacterial	  cells,	  isolated	  colonies	  were	  grown	  overnight	  in	  LB	  with	  10μg/mL	  ampicillin,	  then	  plasmid	  DNA	  was	  isolated	  (as	  described	  above	  in	  DNA	  isolation).	  Clones	  that	  contained	  the	  correct	  mutation	  were	  identified	  by	  DNA	  sequence	  analysis.	  	  	  The	  SUMO	  double	  mutant	  was	  made	  using	  pcDNA	  K249A	  DAX-­‐1	  plasmid	  with	  K362A	  mutagenesis	  primers.	  	  
Mutation	  	   Fwd	  Primer	  5’-­‐3’	   Rev	  Primer	  5’-­‐3’	  K249A	   GCC	  GGT	  GGC	  GCT	  CGC	  GAG	  TCC	  ACA	  GGT	   CGG	  CCA	  CCG	  CGA	  GCG	  CTC	  AGG	  TGT	  CCA	  C	  K362A	   TCC	  CAG	  GTC	  CAA	  GCC	  ATC	  GCG	  TGC	  TTT	  CTT	  TCC	  AAA	  TGC	   GCA	  TTT	  GGA	  AAG	  AAA	  GCA	  CGC	  GAT	  GGC	  TTG	  GAC	  CTG	  GGA	  
	  
Table	  3-­‐5	  Mutagenesis	  primers.	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Cell-­‐Free	  Expression	  Wild-­‐type	  and	  SUMO	  mutant	  DAX-­‐1	  proteins	  	  were	  expressed	  from	  the	  pcDNA	  vector	  containing	  DAX-­‐1	  inserts	  using	  TNT	  T7	  Quick	  Coupled	  Transcription/Translation	  System	  (Promega,	  Madison,	  WI).	  Protein	  was	  synthesized	  as	  per	  the	  manufacturer’s	  protocol	  using	  40μL	  TNT	  T7	  Quick	  Master	  Mix,	  1μL	  1mM	  Methionine,	  2μL	  template	  plasmid	  (1	  μg	  total),	  and	  7μL	  nuclease-­‐free	  water.	  Reactions	  were	  incubated	  at	  30°	  C	  for	  90	  minutes	  to	  complete	  synthesis.	  	  	  
In	  vitro	  SUMOylation	  	  Wild-­‐type	  and	  SUMO	  mutant	  DAX-­‐1	  proteins	  expressed	  in	  vitro	  (TNT	  T7	  Quick	  Coupled	  Transcription	  /Translation	  System)	  were	  used	  as	  template	  with	  an	  in	  vitro	  SUMOylation	  Kit	  (Enzo	  Life	  Sciences,	  Farmingdale,	  NY).	  SUMOylation	  reactions	  for	  SUMO1,	  SUMO2,	  and	  SUMO3	  were	  carried	  as	  per	  manufacturer’s	  protocol	  using	  2μL	  protein.	  Results	  were	  assayed	  by	  western	  blot	  using	  SUMO1	  and	  SUMO2/3	  antibodies	  provided	  with	  the	  kit.	  Blocking	  and	  antibody	  binding	  steps	  utilized	  3%	  bovine	  serum	  albumen	  (BSA)	  in	  phosphate	  buffered	  saline	  with	  0.5%	  Tween	  20	  (1X	  PBS-­‐T).	  	  	  Co-­‐Immunoprecipitation	  (Co-­‐IP)	  	  To	  detect	  the	  presence	  of	  SUMOylation	  on	  DAX-­‐1,	  Co-­‐IP	  was	  carried	  out	  in	  several	  mammalian	  cell	  lines.	  Cells	  were	  collected	  and	  lysed	  as	  described	  previously	  (Protein	  Isolation).	  Whole	  cell	  lysates	  were	  mixed	  with	  Protein	  G	  Magnetic	  Beads	  (New	  England	  BioLabs,	  Ipswich,	  MA)	  to	  eliminate	  non-­‐specific	  binding	  of	  protein	  to	  beads.	  Beads	  were	  removed	  from	  lysates	  and	  discarded	  after	  one	  hour	  incubation	  with	  rotation	  at	  4°	  C.	  DAX-­‐1	  mouse	  primary	  antibody	  was	  added	  and	  incubated	  with	  rotation	  at	  4°	  C	  overnight.	  Beads	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were	  washed	  three	  times	  with	  500μL	  RIPA	  lysis	  buffer	  (Boston	  BioProducts,	  Worcester,	  MA)	  with	  Halt	  Protease	  Inhibitor	  (Thermo	  Fisher	  Scientific,	  Rockford,	  IL)	  added	  at	  a	  concentration	  of	  1:100.	  Washed	  beads	  were	  resuspended	  in	  4X	  NuPAGE	  LDS	  sample	  loading	  buffer	  and	  10X	  NuPAGE	  sample	  reducing	  agent	  and	  electrophoresed	  through	  a	  4-­‐12%	  gel.	  Proteins	  were	  transferred	  onto	  PVDF	  membranes	  and	  western	  blot	  analysis	  was	  carried	  out	  using	  SUMO	  1,	  SUMO	  2/3,	  and	  DAX-­‐1	  antibodies.	  	  	  
 Cell	  Cycle	  Analysis	  	  MCF7	  cells	  were	  grown	  in	  6	  well	  plates	  and	  transfected	  with	  wild-­‐type	  DAX-­‐1	  or	  SUMO	  mutant	  DAX-­‐1	  plasmids	  (previously	  described).	  Cells	  were	  collected	  and	  pelleted	  by	  centrifugation	  at	  5,000	  g	  for	  5	  minutes,	  resuspended	  and	  washed	  in	  500μL	  PBS,	  and	  centrifuged	  at	  5,000	  g	  for	  5	  minutes.	  Supernatant	  was	  removed.	  Cells	  were	  resuspended	  in	  50μL	  PBS,	  and	  mixed	  with	  500μL	  of	  100%	  ethanol.	  Cells	  were	  stored	  overnight	  at	  -­‐20°C.	  Cells	  were	  centrifuged	  at	  5,000	  g	  for	  5	  minutes	  and	  supernatant	  was	  removed.	  Cells	  were	  resuspended	  with	  100μL	  PI/RNase	  Staining	  Buffer	  (BD	  Pharmingen,	  San	  Diego,	  CA)	  and	  10μL	  Propidium	  Iodide	  Staining	  Solution	  (BD	  Pharmingen,	  San	  Diego,	  CA)	  was	  added	  and	  incubated	  for	  10	  minutes	  before	  analysis	  by	  flow	  cytometry,	  using	  the	  BD	  Acurri	  C6	  (BD	  Biosciences,	  San	  Jose,	  CA)	  flow	  cytometer.	  Cell cycle analysis samples were run in duplicate. 
Statistical significance calculated by using two tailed T-test comparing untreated and transfected 
groups. Data found to be statistically significant (p< 0.05) is indicated by asterisks.  	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Apoptosis	  Analysis	  	  MCF7	  cells	  were	  grown	  in	  6	  well	  plates	  and	  transfected	  with	  wild-­‐type	  DAX-­‐1	  or	  SUMO	  mutant	  DAX-­‐1	  plasmids	  (previously	  described).	  Cells	  were	  collected	  and	  pelleted	  by	  centrifugation	  at	  5,000	  g	  for	  5	  minutes,	  resuspended	  and	  washed	  in	  500μL	  PBS,	  and	  centrifuged	  at	  5,000	  g	  for	  5	  minutes.	  Supernatant	  was	  removed.	  Cells	  were	  resuspended	  with	  100μL	  1X	  binding	  buffer	  (10X	  solution	  contains	  0.1	  M	  Hepes	  pH	  7.4,	  1.4	  M	  NaCl,	  25	  mM	  CaCl2)	  and	  mixed	  with	  10μL	  Propidium	  Iodide	  Staining	  Solution	  (BD	  Pharmingen,	  San	  Diego,	  CA)	  and	  5μL	  FITC	  Annexin	  V	  (BD	  Pharmingen,	  San	  Diego,	  CA).	  Cells	  were	  incubated	  for	  10	  minutes	  before	  analysis	  by	  flow	  cytometry,	  using	  the	  BD	  Acurri	  C6	  (BD	  Biosciences,	  San	  Jose,	  CA)	  flow	  cytometer.	  Apoptosis analysis samples were run in duplicate. Statistical 
significance calculated by using two tailed T-test comparing untreated and transfected groups. 
Data found to be statistically significant (p< 0.05) is indicated by asterisks.  	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Chapter 3: Results 
 
Determination of DAX-1 SUMOylation Status 
 In order to determine the SUMOylation status of DAX-1, the predictive software, Abgent 
SUMOplot was used to analyze the amino acid sequence of DAX-1. The analysis revealed 
several putative sites with varying scores (Figure 3-1). This indicated that DAX-1 had a strong 
probability of being SUMOylated. In order to confirm DAX-1 was, in fact, SUMOylated in cells 
a co-immunoprecipitation (Co-IP) experiment was performed using several human cell lines, 
including normal and disease states (Figure 3-2). Whole cell lysates were collected from each 
cell line and incubated with a DAX-1 antibody overnight. Antibody and bound DAX-1 protein 
was isolated using magnetic protein G beads. The presence of SUMO-1 and SUMO-2/3 on 
immunoprecipitated DAX-1 was assayed by western blot. It was found that SUMOylated DAX-1 
was present in all cell lines tested (Table 3-6). The different isoforms of SUMO were 
differentially expressed in the various cell lines. As seen in Figure 3-2, A549 cells had greater 
SUMO-2/3 levels than SUMO-1 levels when co-immunoprecipitated with DAX-1. SW13, 
MDA-MB-231, MCF7, and MCF10A cells had similar detection levels for both SUMO-1 and 
SUMO-2/3 when compared within the cell line, but had varying levels of SUMOylation between 
the cell lines overall. As a control, a western blot to confirm the presence of DAX-1 was 
included. This data demonstrates that in the cell lines examined, DAX-1 is SUMOylated.  
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Figure 3-1 DAX-1 amino acid sequence and protein map showing putative SUMOylation 
sites. 
DAX-1 amino acid sequence with putative SUMOylation sites shown in red.  Lysine residues at 
positions 249 and 362 were predicted as the highest probability sites for SUMOylation.  
Below: DAX-1 protein map showing location of potential SUMO sites at K249 and K362. 
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Cell Line  Origin  
A549  Lung Carcinoma  
SW13 Adrenal Carcinoma 
MDA-MB-231 Triple Negative Breast Cancer  
MCF10A Normal Mammary Epithelium  
MCF7  Breast Adenocarcinoma  
 
Table 3-6 Cell lines tested for SUMOylation of DAX-1 by Co-IP. 
Five human cell lines were tested for the presence of SUMO proteins on immunoprecipitated 
DAX-1 from whole cell lysates. Four of the five cell lines tested were cancerous and one was 
normal tissue.  
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Figure 3-2 Co-IP of SUMO-1, SUMO-2/3, and DAX-1. 
Five human cell lines listed in Table 3-6 were grown and collected as whole cell lysates. Lysates 
were  immunoprecipitated with DAX-1 antibody and analyzed by western blot for the presence 
of SUMO-1, SUMO-2/3, and DAX-1 (control). Different cell types had varying amounts of each 
type of SUMO, but all were positive for the presence of SUMO.  
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Mutation of DAX-1 putative SUMO sites and in vitro SUMOylation. 
 Once confident that DAX-1 was a bona fide SUMOylation target and that it was 
SUMOylated in A549, SW13, MDA-MB-231, MCF7, and MCF10A cell lines, I wished to 
determine the effects of mutating the putative SUMO sites in the DAX-1 protein. The two 
potential SUMO sites with the highest probability scores were lysine 249 and lysine 362, which 
were therefore selected for mutation. Lysines (K) 249 and 362 were mutated to alanines (A) 
using mutagenic primers that flanked the desired lysine and replaced a single nucleotide to 
change the codon to alanine. A third mutant was designed to contain a double mutation (DM) 
containing both the 249 and 362 lysine to alanine mutations. Mutants were generated with the 
QuikChange Lightning PCR Mutagenesis kit (Aligent Technologies) using pcDNA 3.1 DAX-1 
wild-type plasmid as template and previously mentioned mutagenesis primers.  
 Mutant DAX-1 plasmids K249A, K362A, and the double mutant (DM) along with wild-
type DAX-1 were expressed with a cell-free expression system and were SUMOylated using an 
in vitro SUMOylation kit. The in vitro kit includes reactions for SUMO-1, SUMO-2, and 
SUMO-3. SUMO-2 and SUMO-3 are difficult to distinguish and are bound by the same 
antibody. Each reaction includes one isotype of the SUMO protein and the three enzymes 
required to carry out SUMOylation. The SUMOylated protein samples were then analyzed by 
western blot (Figure 3-3). Mutation of lysine 249 reduced SUMO-1 binding when compared to 
WT, K362A, and DM. Interestingly, K362A was reduced for SUMO-2 binding when compared 
to the WT and other mutants. SUMO-3 had a less clear pattern, however the double mutant 
appeared to be the most reduced when compared to the WT and single mutants.  
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Figure 3-3 in vitro SUMOylation of wild-type and SUMO mutant DAX-1. 
Four plasmids; wild-type DAX-1 (WT), lysine 249 to alanine mutant DAX-1 (K249), lysine 362 
to alanine mutant DAX-1 (K362A), and lysine 249  and 362 to alanine double mutant DAX-1 
(DM) were used to produce protein in vitro.  Protein samples were then SUMOylated using an in 
vitro SUMOylation kit and examined by western blot for the three SUMO types. SUMO-1: K249 
had the weakest signal for SUMO-1 indicating that mutation of lysine 249 decreases SUMO-1 
binding, and that SUMO-1 may bind preferentially at that site. SUMO-2: K362 had the weakest 
signal for SUMO-2 indicating that mutation of lysine 362 decreases SUMO-2 binding, and that 
SUMO-2 may bind preferentially to this site. SUMO-3: K362 had the weakest signal for SUMO-
3 indicating that mutation of lysine 362 decreases SUMO-3 binding, and that SUMO-3 may bind 
preferentially to this site. 
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Effects of SUMO site mutation of DAX-1 on expression on DAX-1 target genes.  
 The changes in detectable SUMO level that were observed with the mutants in the in 
vitro SUMOylation experiments indicated that by eliminating K249 and K362, the ability of 
DAX-1 to become SUMOylated is reduced. This allowed for changes in DAX-1 activity to be 
examined by comparing mutants to wild-type DAX-1. In order to see how these mutants would 
change DAX-1’s ability to function, DAX-1 mutants were transfected into MCF7 human 
adenocarcinoma cells. MCF7 cells have low to undetectable endogenous levels of DAX-1. 
Plasmid transfections of an empty vehicle control (VC), wild-type DAX-1, K249A, K362A, and 
the double mutant were carried out and these results are shown in Figures 3-4 and 3-5. 
 Expression levels of GAPDH (control house keeping gene) and DAX-1 were examined 
by PCR and western blot. Successful transfection of plasmids was confirmed by DAX-1 
detection by PCR as shown in Figure 3-4. DAX-1 protein level was also examined (Figure 3-5). 
Although some DAX-1 protein is detectable in the MCF7 cells, it is far less than what is detected 
in the WT DAX-1 transfected cells. The level of detectable DAX-1 protein is reduced for the 
K249A mutant, which may be due to a loss of protein stability resulting from mutation of the 
SUMOylation site.   
 Once successful transfection of WT DAX-1 and SUMO mutants of DAX-1 in the MCF7 
cells had been confirmed, I sought to examine the effects of SUMOylation of DAX-1 on DAX-1 
target gene expression. Of these genes, estrogen receptor alpha and Cyclin D1 were the initial 
gene targets examined. These targets were chosen because they are regulated by DAX-1, and 
ectopic expression of DAX-1 in DAX-1 deficient MCF7 breast cancer cells leads to a reduction 
in ERα and Cyclin D1 transcription (shown in Chapter 2).  Expression was assayed by PCR as 
shown in Figure 3-6. It was observed that cells transfected with WT DAX-1 had reduced 
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expression levels of both ERα and Cyclin D1 compared to untreated and vehicle control treated 
cells. As a negative repressor of ERα, this was expected and confirms what was seen previously 
in the breast cancer proliferation experiments described in Chapter 2.  
Interestingly, the single SUMO K249 and K362 mutant transfected cells showed higher 
expression levels for ERα and Cyclin D1 than the WT DAX-1 transfected cells (Figure 3-6).  
These results indicate that in cells expressing mutant DAX-1 in which SUMO modifications are 
inhibited, there was a lack of ERα and Cyclin D1 gene repression. These data suggest that 
without SUMOylation, DAX-1 is less effective at repressing its target genes. When the double 
mutant is examined, an even stronger level of repression on ERα and Cyclin D1 is observed. 
There is less detectable expression of these targets in the cells transfected with the double mutant 
than what was detected in WT DAX-1 transfected cells (Figure 3-7, Lanes 3 and 6). This is an 
unexpected result and one that we are seeking to understand in future studies. It was surprising 
that the two single mutants resulted in a less functional version of DAX-1, but that having both 
mutations in the same protein led to a version of DAX-1 that appears to be more capable of 
target gene repression than even the wild-type protein. Perhaps the introduction of two different 
mutations into the DAX-1 sequence may influence protein folding and could possibly change the 
overall structure of the protein, causing it to function differently in the MCF7 cells.  
Next, I examined downstream proliferation markers Ki-67, MCM7, and TOP2A 
previously discussed in chapter 2. Ki-67 is a classically used proliferation marker, MCM7 is an S 
phase protein involved in formation of the replication fork, and TOP2A is an S phase 
topoisomerase that helps to relieve torsional stress during DNA replication top [70-72]. In cells 
transfected with wild-type DAX-1, expression of these three proliferation markers was reduced 
compared to untreated and vehicle control cells  
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Figure 3-4 cDNA levels of DAX-1 and GAPDH in wild-type and SUMO mutant DAX-1 
transfected MCF7 cells. 
GAPDH is a PCR control that should not change or be affected by treatment of cells, therefore 
GAPDH levels should be consistent across all samples and can act as a loading control. PCR of 
the DAX-1 gene is a way to determine if the transfections were successful. Untreated MCF7 
cells typically have very low to undetectable DAX-1 mRNA levels. DAX-1 is only detected in 
the samples where either wild-type or SUMO mutant DAX-1 was transfected.  
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Figure 3-5 Protein levels of DAX-1 and GAPDH in wild-type and SUMO mutant DAX-1 
transfected MCF7 cells. 
GAPDH is a loading control to determine that the same amount of protein was loaded for each 
sample. Untreated MCF7 cells have low DAX-1 protein levels. Wild-type DAX-1 transfected 
cells have higher levels of  DAX-1 protein expression. The K249A mutant has less DAX-1 
protein than wild-type DAX-1 transfected cells. K362A mutant cells have DAX-1 protein levels 
similar to wild-type transfected cells and the double mutant has an intermediate amount of DAX-
1 protein.  
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(Figure 3-7, Lanes 1-3). Since DAX-1 is able to repress ERα and reduce the amount of Cyclin 
D1 being expressed by ERα, reduction of downstream S phase targets genes is expected and was 
observed previously (see Chapter 2).   
When expression of Ki-67, MCM7, and TOP2A was assayed in cells transfected with the  
SUMO mutation DAX-1, it was found that with the two single mutants, K247 and K362, 
demonstrated a higher expression level of target genes compared to the WT DAX-1 treated cells 
(Figure 3-7, Lanes 3-5). A similar result was seen with the ERα and Cyclin D1 genes. Therefore, 
these results demonstrate that elimination of DAX-1’s SUMOylation sites results in a reduction 
in the ability of DAX-1 to repress target genes. The double mutant DAX-1 transfected cells 
showed similar expression to the single mutants for Ki-67, and was slightly less for TOP2A 
(Figure 3-6, Lane 6). However, when expression of MCM7 was examined for the double mutant 
DAX-1 transfected cells, there was a reduction in expression compared to either the single 
mutants or the WT DAX-1 transfected cells. This was somewhat unexpected, as it seems 
unlikely that a double mutant would be more functional than either the single mutants or the 
wild-type DAX-1. Though this result was similar to what was seen for expression of ERα and 
Cyclin D1 (Figure 3-7, Lane 6). These results for the SUMO double mutant transfected cells 
potentially further supports the rationale that there may be some alteration in protein structure  
that occurs when two different sites are mutated that results in a change in DAX-1 function in 
MCF7 cells.   
 
Cell cycle analysis of wild-type and SUMO mutant transfected MCF7 breast cancer cells. 
 Cell cycle analysis by flow cytometry using propidium iodide (PI) staining was used to 
functionally assess the gene expression data. As described in Chapter 2, cell cycle analysis is a  
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Figure 3-6 cDNA levels of ERα and Cyclin D1 in wild-type and SUMO mutant DAX-1 
transfected MCF7 cells. 
Expression of wild-type DAX-1 in MCF7 cells leads to a reduction in ERα and Cyclin D1 
expression levels. K249A and K362A SUMO mutant transfected cells have lower expression 
levels of ERα and Cyclin D1 compared to untreated or vehicle control cells (lanes 4 and 5), but 
higher expression of ERα and Cyclin D1 than wild-type DAX-1 transfected cells. Mutation of 
the SUMO sites leads to a reduction in DAX-1’s ability to repress expression of ERα and Cyclin 
D1. Expression of the double mutant results in the complete repression of ERα and Cyclin D1 
gene expression (lane 6).  
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Figure 3-7 cDNA levels of proliferation markers Ki-67, MCM7, and TOP2A in wild-type 
and SUMO mutant DAX-1 transfected MCF7 cells. 
Expression of wild-type DAX-1 in MCF7 cells leads to a reduction in cDNA level for all three 
proliferation markers Ki-67, MCM7, and TOP2A. K249A and K362A SUMO mutant transfected 
cells have similar Ki-67 and TOP2A expression levels as cells that are untreated and vehicle 
control cells. Expression levels of MCM7 in cells transfected with K249A and K362A mutant 
DAX-1 were lower than untreated and vehicle control cells. Therefore, mutating SUMO sites 
leads to some reduction in DAX-1’s ability to repress expression of Ki-67, MCM7, and TOP2A. 
The double mutant does not exhibit a clear pattern for these three proliferation genes. The double 
mutant is comparable with the K249A and K362A for Ki-67, but completely represses 
expression of MCM7 and has a similar cDNA level with wild-type DAX-1 for TOP2A.  
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method of distinguishing what stage of the cell cycle different populations of cells are in at the 
time of analysis. MCF7 cells were left untreated or transfected with either vehicle control, wild-
type DAX-1, K249A mutant, K362A mutant, or double mutant plasmids. Following a 48 hour 
incubation, cells were collected, stained with PI, and analyzed via flow cytometry. As had been 
previously observed in the experiments in Chapter 2, there was a shift in the wild-type DAX-1 
treated cells, which was found to be statistically significant (p= .018). Specifically, more cells 
were found to be in G0/G1 compared to untreated or vehicle control cells (Figure 3-8a). There 
were 24.2% and 24.7% of cells in G0/G1 for untreated and vehicle control groups respectively 
and 28.9% of cells in G0/G1 for WT DAX-1 treated cells (Figure 3-8b). These data supports my 
previous expression data demonstrating that ERα and Cyclin D1 repression by DAX-1 causes 
more cells to stay in G0/G1 rather than progressing to S phase. Compared to WT DAX-1, no 
significant shift was seen with the SUMO mutants (Figure 3-8a). Cells transfected with the 
K249A, K362A, and double mutant behaved much like the untreated and vehicle control cells. 
When compared with WT DAX-1 cells, a significant shift in percentage of cells in G1/G0 was 
observed in the K249A (p= .026), K362A (p= .047), and double mutants (p= .047). Percentages 
of cells in G0/G1 were 22.9%, 24.4% and 25.4% for the K249A, K362A, and double mutant 
respectively (Figure 3-8b). Interestingly, loss of SUMO binding sites appears to change the 
function or stability of DAX-1, at least to some degree. The repression in proliferation observed 
with wild-type DAX-1 is lost when SUMO sites are mutated, supporting previous expression 
data, with the K249A and K362A mutants. Inhibition of proliferative genes observed with wild-
type DAX-1 transfected cells was reduced when cells were transfected with K249A and K362A 
SUMO mutant DAX-1. Similarly, the inhibition of proliferation seen with wild-type DAX-1  
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Figure 3-8a Cell cycle analysis of wild-type and SUMO mutant DAX-1 transfected MCF7 
cells. 
Wild-type DAX-1 transfected cells had an increase in the proportion of cells in G0/G1 of the 
cells cycle when compared with untreated or vehicle control cells. The proportion of cells in 
G0/G1 for DAX-1 SUMO mutant transfected cells was more similar to untreated and vehicle 
control cells. UT: untreated VC: vehicle control WT: wild-type DAX-1 K249A: K249A SUMO 
mutant K362A: K362A SUMO mutant DM: double mutant. First peak in histogram represents 
proportion of cells in G0/G1 phase of cell cycle and the second peak represents cells in G2/M 
phase of cell cycle. 
(Refer to Chapter 2 for diagram of cell cycle analysis methodology) 
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Figure 3-8b Quantification of cell cycle analysis of wild-type and SUMO mutant DAX-1 
transfected cells.  
Quantification of cell cycle analysis data shown in Figure 3-8a, graph represents proportion of 
cells for each treatment group that were in G0/G1 of the cell cycle.  
P<0.05 * 
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transfected cells was lost when cells were transfected with K249A and K362A SUMO mutant 
DAX-1.  
 
Apoptosis analysis by annexin V of wild-type and SUMO mutant DAX-1 transfected MCF7 
breast cancer cells.  
 
 I have shown that DAX-1 acts to slow growth and proliferation through repression of 
ERα and its transcription target Cyclin D1. However, it is unknown if DAX-1 plays any role in 
apoptosis. The goal of these experiments was to determine if expression of DAX-1 induces 
apoptosis more readily than untreated cells and to evaluate differences between the action of 
wild-type DAX-1 compared to the DAX-1 SUMO mutants. 
Apoptosis analysis involves fluorescence detection of Annexin V and PI to determine 
whether cells are healthy or if they are entering early or late stage apoptosis [73, 74]. Annexin V 
stains phosphatidylserine (PS), a phospholipid membrane component that is only found on the 
inner leaflet of the cell membrane in healthy cells. During early apoptosis, phosphatidylserine 
flips from the inner layer of the membrane to the outer layer of the membrane. Cells that are 
positive for Annexin V staining are in the early stages of apoptosis. Propidium iodide (PI) stains 
DNA and can only penetrate cells that have lost membrane integrity due to late stage apoptosis 
or necrosis. Cells that stain for Annexin V alone are in early apoptosis. Cells with both Annexin 
and PI staining are in the later stages of apoptosis. Cells stained with PI alone have undergone 
some mechanical damage or are necrotic. A sample plot is shown in Figure 3-9. 
In these experiments the focus was primarily on cells entering early and late stages of apoptosis. 
MCF7 cells were transfected as before, with either vehicle control, wild-type DAX-1, or SUMO 
mutant DAX-1 (in pcDNA3.1) and incubated for 48 hours before collection. Collected cells were 
co-stained with Annexin V and PI prior to stain detection by flow cytometry. 
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Figure 3-9 Annexin V/PI apoptosis analysis diagram.  
Normally phosphatidylserine is found only on the inner leaflet of the plasma membrane, however 
during early stages of apoptosis phosphatidylserine flips from the inner to the outer leaflet of the 
membrane. Annexin V stains phosphatidylserine and produces a signal detectable by flow 
cytometry. PI stains DNA and cannot enter cells unless a loss of membrane integrity has 
occurred. Loss of membrane integrity can be attributed to late stage apoptosis or necrosis. Viable 
cells without any staining will localize to the lower left quadrant. Cell with only PI staining are 
necrotic and will be found in the upper left quadrant. Cell in early apoptosis will stain with for 
Annexin V only and will be found in the lower right quadrant. Cells in later stages of apoptosis 
will have co-staining for both Annexin V and PI and will be found in the upper right quadrant.  
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Untreated and vehicle control cells yielded similar plots with 1.8% (UT) and 1.7% (VC) of cells 
in early apoptosis and 4.4% (UT) and 3.0% (VC) in late apoptosis (Figure 3-10a and b). Wild-
type DAX-1 expressing cells presented a strong shift with 33.0% of cells in early apoptosis and 
8.1% of cells in late apoptosis (Figure 3-10a and b). The SUMO mutant transfected cells more 
closely resembled the UT and VC cells compared to the WT DAX-1 treated cells. SUMO mutant 
DAX-1 treated cells had 5.5% (K249A), 5.7% (K362A), and 0.6% (DM) of cells in early 
apoptosis and 5.6% (K249A), 7.4% (K362A), and 2.3% (DM) of cells in later apoptosis (Figure 
3-10a and b). The single mutants had greater populations of cells in early and late apoptosis than 
untreated and vehicle control cells, but had far fewer cells in early apoptosis than wild-type 
DAX-1 cells. The double mutant had values that were a closer match to the untreated and control 
cells for early and late apoptosis.  
 These data echo what was seen in previous experiments performed with the DAX-1 
SUMO mutants. With SUMO sites mutated, DAX-1 is unable to function as it does in its native 
state. The repressive ability of DAX-1 is reduced with the mutations, as is the ability of DAX-1 
to slow proliferation and induce apoptosis. While still preliminary, the apoptosis data indicates 
that DAX-1 may have a role not only in proliferation, but also in programed cell death. More 
studies into the role of DAX-1 are needed and are part of future experiments to be carried out in 
the Tzagarakis-Foster lab.  
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Figure 3-10a Apoptosis analysis of wild-type and SUMO mutant DAX-1 transfected cells 
by Annexin V/PI staining.  
Wild-type DAX-1 transfected cells produced a strong shift in proportion of cells undergoing 
early apoptosis. SUMO mutants K249A and K362A had a small shift, but overall had a 
distribution that was more similar to untreated and vehicle control cells than to wild-type DAX-1 
transfected cells. The double mutant transfected cells had similar distributions of cells in early 
and late apoptosis, but had more cells than any other treatment group undergoing necrosis.  
UT: untreated VC: vehicle control WT: wild-type DAX-1 K249A: K249A SUMO mutant 
K362A: K362A SUMO mutant DM: double mutant.  
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Figure 3-10b Quantification of Apoptosis analysis in wild-type and DAX-1 SUMO mutant 
transfected cells by Annexin V/PI staining.  
Quantification of proportion of cells in each treatment group stained with Annexin V (early 
apoptosis) or Annexin V and PI (late apoptosis). Annexin V: UT 1.8%,  VC 1.7%, DAX 33%, 
K249A 5.5%, K362A 5.7%, and DM 0.6%. Annexin/PI: UT 4.4%, VC 3.0%, DAX 8.1%, 
K249A 5.6%, K362A7.4%, and DM 2.3%. Significance based on comparison of UT and 
transfected groups for staining of Annexin V alone or Annexin V and PI. 
P<0.05 *  
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Chapter 3: Discussion and Future Directions 
 
SUMOylation of target proteins has been shown to have a variety of effects and may play 
a critical role in regulating function. Research has shown that mutation of the SUMO sites within 
SF-1, an NHR closely related to DAX-1, resulted in abnormal endocrine development [69, 75, 
76].  These studies influenced our desire to determine the SUMOylation status of DAX-1 and to 
elucidate the effect that SUMOylation has on the function of DAX-1. In this research, I 
determined that DAX-1 is, in fact, SUMOylated in cell lines and that mutation of predicted 
SUMO sites resulted in changes in DAX-1’s ability to repress transcription of target genes. 
Wild-type DAX-1 is able to repress the transcriptional activity of ERα, thereby reducing the 
expression of Cyclin D1, a direct target of ERα. When the predicted SUMO sites within DAX-1, 
K249 and K361, were mutated, repression of ERα and Cyclin D1 was reduced when compared 
with WT DAX-1. This helps to support the hypothesis that SUMOylation of DAX-1 is important 
for its proper function. A similar result was seen when three S phase proliferation markers were 
examined. That is, expression of WT DAX-1 reduced the expression of these genes, whereas the 
expression of the single DAX-1 SUMO mutants led to a reduction in repression compared to WT 
DAX-1.  
There were unexpected results obtained with the DAX-1 SUMO double mutant. 
Specifically, ERα, Cyclin D1, MCM7, and TOP2A were repressed to a greater degree when the 
double mutant was expressed than they were with WT DAX-1. Interestingly, for Ki-67, the 
double mutant had a similar level of expression to the single mutants K249A and K362A. The 
variation seen with the double mutant was unexpected, as was the fact that for the majority of the 
targets tested the double mutant reduced expression of the proliferation markers more than WT 
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DAX-1.  One possible explanation for this observation is that by changing two lysine residues to 
alanines, we have unintentionally changed the folding and three-dimensional shape of DAX-1. 
Lysine is a positively charged amino acid, whereas alanine is a non-polar amino acid. Therefore, 
changing lysine residues to alanine could potentially change the way a particular region of the 
DAX-1 protein folds. Perhaps changing these to two residues shifted the positioning of the 
protein such that it is able to bind more tightly to the promoter region of ERα and prevent 
transcription. In order to address the issues that arose with the double K to A mutant more 
experiments will be conducted.  
For example, since there are unintended consequences of replacing positively charged 
lysine with non-polar alanine, additional mutants are being constructed that replace lysine with 
arginine (R). Arginine is positively charged and is much more similar to lysine than alanine. 
Future SUMOylation studies will be performed using K249R, K362R, and R double mutants. 
These studies will help to confirm that mutation of putative SUMO sites change the function of 
DAX-1 and leads to a reduction in repressional ability. Additionally, these experiments should 
help to explain the results that were observed using the alanine double SUMO mutant, 
specifically to address if the inconsistencies were due to some conformational changes from 
alanine or if there is some unknown consequence of mutating both putative SUMO sites.  
The apoptosis analysis data for wild-type DAX-1 was quite striking and needs to be 
further explored. Other research in the Tzagarakis-Foster laboratory has revealed interactions 
with DAX-1 and the apoptotic Bcl-2 family. To date, research with DAX-1 has been primarily 
focused on proliferation, however this preliminary data suggests that DAX-1 may play an even 
more significant role in promoting apoptosis by way of repressing anti-apoptotic genes. This may 
be a very promising new avenue to explore in DAX-1 research.  
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